

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> :  A61K 39/112, 39/02, 39/108, 39/106, 39/102, 39/10, 39/095, C12N 1/20, 1/21, 1/36, 15/74, A61P 31/04 // (C12N 1/20, C12R 1:42)		A1	(11) International Publication Number: <b>WO 00/45840</b>
			(43) International Publication Date: 10 August 2000 (10.08.00)
(21) International Application Number: PCT/US00/02866		(74) Agents: POLIZZI, Catherine, M. et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).	
(22) International Filing Date: 2 February 2000 (02.02.00)			
(30) Priority Data: 09/241,951 2 February 1999 (02.02.99) US 09/305,603 5 May 1999 (05.05.99) US Not furnished 1 February 2000 (01.02.00) US		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except US): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 12th floor, 1111 Franklin Street, Oakland, CA 94607-5200 (US).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): MAHAN, Michael, J. [US/US]; 5333 Cameo Paseo, Santa Barbara, CA 93111 (US). HEITHOFF, Douglas, M. [US/US]; Apartment 404, 6750 El Colegio, Goleta, CA 93117 (US). LOW, David, A. [US/US]; 6089 La Goleta Road, Goleta, CA 93117 (US). SINSHEIMER, Robert, L. [US/US]; 4606 Via Cayente, Santa Barbara, CA 93110 (US).			
(54) Title: COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING PATHOGENIC BACTERIAL INFECTION BASED ON THE ESSENTIAL ROLE OF DNA METHYLATION IN BACTERIAL VIRULENCE			
(57) Abstract			
<p>The present invention is directed towards vaccine compositions containing pathogenic bacteria such as <i>Salmonella</i> having non-reverting genetic mutations which alter activity of DNA adenine methylase (Dam) and methods using these compositions to elicit an immune response. The invention also provides methods for preparing vaccines as well as screening methods to identify agents which may have anti-bacterial activity.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

**COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING  
PATHOGENIC BACTERIAL INFECTION BASED ON THE ESSENTIAL ROLE  
OF DNA METHYLATION IN BACTERIAL VIRULENCE**

5

**CROSS-REFERENCE TO OTHER APPLICATIONS**

This patent application claims the priority benefit of U.S. patent application Serial Nos.09/241,951, filed February 2, 1999, converted to U.S. Provisional Ser. No. \_\_\_\_\_, 10 and 09/305,603, filed May 5, 1999, converted to U.S. Provisional Ser. No. \_\_\_\_\_, which are incorporated by reference in their entirety.

**STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER FEDERALLY  
SPONSORED RESEARCH**

15 This invention was made with Government support under Grant Nos. AI36373 (to M. Mahan) and AI23348 (to D. Low), awarded by the National Institutes of Health. The Government may have certain rights in this invention.

**FIELD OF THE INVENTION**

20 The present invention relates to vaccines useful for the prevention or modification of microbial pathogenesis. In particular, this invention relates to immunogenic compositions generally comprising pathogenic bacteria (e.g., *Salmonella*) which contain a mutation affecting DNA adenine methylase (Dam). The invention also relates to methods of eliciting an immune response using these compositions, as well as screening methods.

25

**BACKGROUND OF THE INVENTION**

Food-borne disease presents a serious threat to our health, the safety of the nation's food supply, and to the agricultural industry. Each year over 80 million Americans suffer 30 from food poisoning, at a cost estimated between \$5 and \$23 billion annually in medical

treatment and lost wages (Snydman, D. R., *Food poisoning*. In: *Infectious Diseases*, second edition, Gorbach, S. L., *et al.*, eds., 768-781 (1998)). Our defenses against food-borne disease are failing as new pathogens have emerged that can cause more debilitating forms of disease and/or can no longer be controlled by available antibiotics; examples

5 include *Escherichia coli* (*E. coli*) 0157:H7, *Salmonella enteritidis* (*S. enteritidis*), and *S. typhimurium* DT104 (Alterkruse, S. F., *et al.*, *Emerging food borne diseases*, 3: July-Sept. (1997)). Salmonellosis is one of the major food-borne diseases in the United States, estimated at between 1 and 4 million cases/year (Shere, K. D., *et al.*, *Salmonella infections*. In: *Infectious Diseases*, second edition, Gorbach, S. L., *et al.*, eds., 699-712 (1998)). This

10 disease is caused by exposure to products contaminated with Salmonella, e.g., animal products such as eggs, milk, poultry or the ingestion of food products that have been exposed to animal feces, including fruits and vegetables. Due to large scale manufacturing and distribution practices, salmonellosis outbreaks have affected large populations (Tauxe, R. V., *et al.*, *Emerging food borne diseases: an evolving public health challenge*.

15 *Emerging infectious diseases*, 3:Oct-Dec (1997)).

Salmonella is a prime example of a pathogenic microorganism whose various species are the cause of a spectrum of clinical diseases that include acute gastroenteritis and enteric fevers. Salmonella infections are acquired by oral ingestion. The microorganisms after traversing the stomach, invade and replicate in the intestinal mucosal cells. See,

20 Hornik, *et al.*, *N. Eng. J. Med.*, 283:686 (1970). Some species, such as *S. typhi*, can pass through this mucosal barrier and spread via the Peyer's patches to the lamina propria and regional lymph nodes. *Salmonella typhi*, which only infects man, is the cause of typhoid fever and continues to be an important public health problem for residents in the less developed world.

25 Urinary tract infections (UTI) are among the most common bacterial infections. It is estimated that about 20% of women will experience at least one UTI during their

lifetime. Although women are the major target of UTI, men and children can also contract this disease. About 70% of all UTI are caused by uropathogenic *Escherichia coli*. The disease may be limited to the lower urinary tract (cystitis) or can involve the renal pelvis (pyelonephritis). Over 90% of *E. coli* isolated from women with pyelonephritis contain the 5 pyelonephritis-associated pili (*pap*) gene cluster (O'Hanley, P. M., *et al.*, *N. Engl. J. Med.*, 313:414-447 (1985)). Most patients with pyelonephritis caused by *E. coli* mount a strong immune response to Pap pili. The Pap pili contain adhesins at their tips that enable these bacteria to colonize the urinary tract, *id*. Most Pap pili-adhesin complexes bind to the P blood group receptor, which is expressed on epithelial cells lining the gut, the bladder, and 10 ureters. Despite our understanding of the role of adhesion in the pathogenesis of UTI, no vaccine is available against UTI. This is also true for many other important microbial pathogens that cause significant morbidity and mortality.

Microbial pathogens, or disease-producing microorganisms, can infect a host by one of several mechanisms. They may enter through a break in the skin, they may be 15 introduced by vector transmission, or they may interact with a mucosal surface. Disease ensues following infection of the host, when the potential of the pathogen to disrupt normal bodily functions is fully expressed.

Each disease-producing microorganism possesses a collection of virulence factors that enhance their pathogenicity and allow them to invade host or human tissues and disrupt 20 normal bodily functions. Infectious diseases have been major killers over the last several thousand years, and while vaccines and antimicrobial agents have played an important role in the dramatic decrease in the incidence of infectious diseases, infectious diseases are still the number one cause of death world-wide.

Environmental conditions within the host are responsible for regulating the 25 expression of most known virulence factors (Mekalanos, J. J., *J. Bacteriol.*, 174:1 (1992)). In the past, scientists would attempt to mimic, *in vitro*, the environmental conditions within

the host in an attempt to identify those genes that encode and are responsible for producing virulence factors. As a result, the identification of many virulence factors was dependent on, and limited by, the ability of researchers to mimic host environmental factors in the laboratory. However, with the advent of *in vivo* expression technology (IVET) discovered 5 by Mahan, M. J., *et al.*, and disclosed in U. S. Patent No. 5,434,065 it is now possible to determine which genes are expressed within a host and within which tissues of the host the genes are expressed. Consequently, the molecular mechanisms of the specific pathogenic microorganisms that allow them to circumvent the host's (e.g., human body) immune system and initiate the physiological changes inherent in the disease process can be 10 elucidated, thus allowing for the development of better therapeutic and diagnostic approaches against pathogenic microbes.

Along with water sanitation, prevention of infectious diseases by vaccination is the most efficient, cost-effective, and practical method of disease prevention. No other modality, not even antibiotics, has had such a major effect on mortality reduction and 15 population growth. The impact of vaccination on the health of the world's people is hard to exaggerate. Vaccination, at least in parts of the world, has controlled the following nine major diseases: smallpox, diphtheria, tetanus, yellow fever, pertussis, poliomyelitis, measles, mumps and rubella. In the case of smallpox, the disease has been totally eradicated from the world. The effectiveness of a vaccine depends upon its ability to elicit 20 a protective immune response, which will be generally described below.

The means by which vertebrates, particularly birds and mammals, overcome microbial pathogenesis is complex. Pathogens that invade a host provoke a number of highly versatile and protective systems. If the microbial pathogen or its toxins successfully penetrate the body's outer defenses and reach the bloodstream, then the lymphoid tissue of 25 the spleen, liver, and bone marrow will remove and destroy the foreign material as the blood circulates through these organs. Lymphoid tissue is composed primarily of a

meshwork of interlocking reticular cells and fibers. Clinging to the interstices of the tissues are large numbers of leukocytes, more specifically, lymphocyte cells, and other cells in various stages of differentiation, such as plasma cells, lymphoblasts, monocyte-macrophages, eosinophils and mast cells. The two main lymphocytes, T cells and B cells, 5 have different and complementary roles in the mediation of the antigen-specific immune response.

The immune response is an exceedingly complex and valuable homeostatic mechanism that has the ability to recognize foreign pathogens. The initial response to foreign pathogen is called "innate immunity" and is characterized by the rapid migration of 10 natural killer cells, macrophages, neutrophils, and other leukocytes to the site of the foreign pathogen. These cells can either phagocytose, digest, lyse, or secrete cytokines that lyse the pathogen in a short period of time. The innate immune response is not antigen-specific and is generally regarded as a first line of defense against foreign pathogens until the "adaptive immune response" can be generated. Both T cells and B cells participate in the 15 adaptive immune response. A variety of mechanisms are involved in generating the adaptive immune response. A discussion of all the possible mechanisms of generating the adaptive immune response is beyond the scope of this section, however, some mechanisms which have been well-characterized include B cell recognition of antigen and subsequent activation to secrete antigen-specific antibodies and T cell activation by binding to antigen 20 presenting cells.

Microbial organisms can have cell membranes that are recognized as foreign by the immune system. In addition, microbial organisms may also produce toxins or proteins that are also considered foreign by the host's immune system. The first mechanism mentioned above involves the binding of antigen, such as bacterial cell wall or bacterial toxin, to the 25 surface immunoglobulin receptors on B cells. The receptor binding transmits a signal to the interior of the B cell. This is what is commonly referred in the art as "first signal". In

some cases, only one signal is needed to activate the B cells. These antigens that can activate B cell without having to rely on T cell help are commonly referred to as T-independent antigens (or thymus-independent antigens). In other cases, a "second signal" is required and this is usually provided by T helper cells binding to the B cell. When T cell

5 help is required for the activation of the B cell to a particular antigen, the antigen is then referred to as T-dependent antigen (or thymus-dependent antigen). In addition to binding to the surface receptors on the B cells, the antigen can also be internalized by the B cell and then digested into smaller fragment within the B cell and presented on the surface of B cells in the context of antigenic peptide-MHC class II molecules. These peptide-MHC class II

10 molecules are recognized by T helper cells that bind to the B cell to provide the "second signal" needed for some antigens. Once the B cell has been activated, the B cells begin to secrete antibodies to the antigen that will eventually lead to the inactivation of the antigen. Another way for B cells to be activated is by contact with follicular dendritic cells (FDCs) within germinal centers of lymph nodes and spleen. The follicular dendritic cells trap

15 antigen-antibody (Ag-Ab) complexes that circulate through the lymph node and spleen and the FDCs present these to B cells to activate them.

Another well-characterized mechanism of adaptive immune response to antigens is the activation of T cells by binding to antigen presenting cells such as macrophages and dendritic cells. Macrophages and dendritic cells are potent antigen presenting cells.

20 Macrophages have a variety of receptors that recognize microbial constituents such as macrophage mannose receptor and the scavenger receptor. These receptors bind microorganisms and the macrophage engulfs them and degrades the microorganisms in the endosomes and lysosomes. Some microorganisms are destroyed directly this way. Other microorganisms are digested into small peptides that are then presented to T cells on the

25 surface of the macrophages in the context of MHC class II-peptide complexes. T cells that bind to these complexes become activated. Dendritic cells are also potent antigen

presenting cells and present peptide-MHC class I molecules and peptide-MHC class II molecules to activate T cells.

When a B cell binds to an antigen which has never been encountered, the cell undergoes a developmental pathway called "isotype switching". During the developmental changes, the plasma cells switch from producing general IgM type antibodies to producing highly specific IgG type antibodies. Within this population of cells, some undergo repeated divisions in a process called "clonal expansion". These cells mature to become antibody factories that release immunoglobulins into the blood. When they are fully mature, they become identified as plasma cells, cells that are capable of releasing about 2,000 identical antibody molecules per second until they die, generally within 2 or 3 days after reaching maturity. Other cells within this group of clones never produce antibodies but function as memory cells that will recognize and bind that particular antigen upon encountering the antigen.

As a consequence of the initial challenge by an antigen there are now many more cells identical to the original B cell or parent cell, each of which is able to respond in the same way to the antigen as the original B cell. Consequently, if the antigen appears a second time, it will encounter one of the correct B cells sooner, and since these B cells are programmed for the specific IgG antibody, the immune response will begin sooner, accelerate faster, be more specific and produce greater numbers of antibodies. This event is considered a secondary or anamnestic response. Figure 1 shows a comparison of the antibody titer present as a result of the primary and secondary responses. Immunity can persist for years because memory cells survive for months or years and also because the foreign material is sometimes reintroduced in minute doses that are sufficient to constantly trigger low-level immune responses. In this way the memory cells are periodically replenished.

Following the first exposure to an antigen the response is often slow to yield antibody and the amount of antibody produced is small, i.e., the primary response. On secondary challenge with the same antigen, the response, i.e., the secondary response, is more rapid and of greater magnitude thereby achieving an immune state equal to the

5     accelerated secondary response following reinfection with a pathogenic microorganism, which is the goal that is sought to be induced by vaccines.

In general, active vaccines can be divided into two general classes: subunit vaccines and whole organism vaccines. Subunit vaccines are prepared from components of the whole organism and are usually developed in order to avoid the use of live organisms that

10    may cause disease or to avoid the toxic components present in whole organism vaccines, as discussed in further detail below. The use of purified capsular polysaccharide material of *H. influenza* type b as a vaccine against the meningitis caused by this organism in humans is an example of a vaccine based upon an antigenic component. See Parks, *et al.*, *J. Inf. Dis.*, 136 (Suppl.):551 (1977), Anderson, *et al.*, *J. Inf. Dis.*, 136 (Suppl.):563 (1977); and

15    Mäkela, *et al.*, *J. Inf. Dis.*, 136 (Suppl.):543 (1977).

Classically, subunit vaccines have been prepared by chemical inactivation of partially purified toxins, and hence have been called toxoids. Formaldehyde or glutaraldehyde have been the chemicals of choice to detoxify bacterial toxins. Both diphtheria and tetanus toxins have been successfully inactivated with formaldehyde resulting in a safe and effective toxoid vaccine which has been used for over 40 years to control diphtheria and tetanus. See, Pappenheimer, A. M., *Diphtheria*. In: *Bacterial Vaccines* (R. Germanier, ed.), Academic Press, Orlando, FL, pp. 1-36 (1984); Bizzini, B., *Tetanus*. *Id.* at 37-68. Chemical toxoids, however, are not without undesirable properties. In fact, this type of vaccine can be more difficult to develop since protective antigens must first be identified and then procedures must be developed to efficiently isolate the antigens. Furthermore, in some cases, subunit vaccines do not elicit as strong an immune response as

do whole organism vaccines due to the lack of extraneous materials such as membranes or endotoxins that may be more immunogenic due to the removal of materials that would otherwise mask the protective antigens or that are immunodominant.

Whole organism vaccines, on the other hand, make use of the entire organism for vaccination. The organism may be killed or alive (usually attenuated) depending upon the requirements to elicit protective immunity. The pertussis vaccine, for example, is a killed whole cell vaccine prepared by treatment of *Bordetella pertussis* cells with formaldehyde. The bacterium *B. pertussis* colonizes the epithelial lining of the respiratory tract resulting in a highly contagious respiratory disease in humans, pertussis or whooping cough, with morbidity and mortality rates highest for infants and young children. The colonization further results in local tissue damage and systemic effects caused in large part by toxins produced by *B. pertussis*. See, Manclarck, *et al.*, Pertussis., *Id.* at 64-106. These toxins include endotoxin or lipopolysaccharide, a peptidoglycan fragment called tracheal cytotoxin, a heat-labile dermonecrotizing protein toxin, an adenylated cyclase toxin, and the protein exotoxin pertussis toxin. Vaccination is the most effective method for controlling pertussis, and killed whole-cell vaccines administered with diphtheria and tetanus toxoids (DPT vaccine) have been effective in controlling disease in many countries. See, Fine, *et al.*, Reflections on the Efficacy of Pertussis Vaccines, *Rev. Infect. Dis.*, 9:866-883 (1987). Unfortunately, due to the large amounts of endogenous products, discussed above, contained in the pertussis vaccine, many children experience adverse reactions upon injection. Endotoxin, which is an integral component of the outer membrane of the gram-negative organism (as well as all other gram-negative organisms), can induce a wide range of mild to severe side effects including fever, shock, leukocytosis, and abortion. While the side effects associated with pertussis vaccine usually are mild, they may be quite severe. The toxic components present in influenza virus vaccines, however, can induce a strong pyrogenic response and have been responsible for the production of Guillain-Barré

syndrome. Since influenza vaccines are prepared by growth of the virus in chick embryos, it is likely that components of the embryo or egg contributes to this toxicity.

The use of killed vaccines has also been described by Switzer *et al.*, U.S. Patent No. 4,016,253, who applied such a method in preparing a vaccine against *Bordetella bronchiseptica* infection in swine. In a technical paper by Brown, *et al.*, *Br. Med. J.*, 1:263 (1959), the use of killed whole cells is disclosed for preparing a vaccine against chronic bronchitis caused by *Haemophilus influenzae*. The use of killed cells, however, is usually accompanied by an attendant loss of immunogenic potential, since the process of killing usually destroys or alters many of the surface antigenic determinants necessary for induction of specific antibodies in the host. Killed vaccines are ineffective or marginally effected for a number of pathogenic bacteria including *Salmonella spp.* and *V. cholerae*. The parenteral killed whole cell vaccine now in use for *Salmonella typhi* is only moderately effective, and causes marked systemic and local adverse reactions at an unacceptably high frequency.

In the case of intracellular pathogens, such as *Salmonella*, it is generally agreed that vaccines based on live but attenuated microorganisms (live vaccines) induce a highly effective type of immune response. Live attenuated vaccines are comprised of living organisms that are benign but typically can replicate in a host tissues and presumably express many natural target immunogens that are processed and presented to the immune system similar to a natural infection. This interaction elicits a protective response as if the immunized individual had been previously exposed to the disease. Most of the work defining attenuating mutations for the construction of live bacterial vaccines has been performed in *S. spp.* since they establish an infection by direct interaction with the gut associated lymphoid tissue (GALT), resulting in a strong humoral immune response. They also invade host cells and thus are capable of eliciting a strong cell mediated response.

Eisenstein (1999) *Intracellular Bacterial Vaccine Vectors* (Paterson, ed., Wiley-Liss, Inc.)

pp. 51-109; Hone et al. (1999) *Intracellular Bacterial Vaccine Vectors* (Paterson, ed., Wiley-Liss, Inc.) pp. 171-221; Sirard et al. (1999) *Immun. Rev.* 171:5-26. Ideally, these attenuated microorganisms maintain the full integrity of cell-surface constituents necessary for specific antibody induction yet are unable to cause disease, because, for example, they

5 fail to produce virulence factors, grow too slowly, or do not grow at all in the host. Additionally, these attenuated strains should have substantially no probability of reverting to a virulent wild-type strain. Traditionally, live vaccines have been obtained by either isolating an antigenically related virus from another species, by selecting attenuation through passage and adaptation in a nontargeted species or in tissue cultures, or by

10 selection of temperature-sensitive variants. The first approach was that used by Edward Jenner who used a bovine poxvirus to vaccinate humans against smallpox.

Selecting attenuation through serial passages in a nontargeted species is the second approach that has been widely successful in obtaining live vaccines. For example, Parkman, et al., *N. Engl. J. Med.*, 275:569-574 (1966), developed an attenuated rubella

15 vaccine after serial multiplication in green monkey kidney cells. A measles vaccine has been prepared by passaging the virus in chick embryo fibroblasts. Vaccines against, polio, hepatitis A, Japanese B encephalitis, dengue, and cytomegalovirus have all been prepared following similar procedures.

While animal models, and especially monkeys, are useful in developing live

20 vaccines by serial passages and selection, a large uncertainty as to whether a vaccine is truly nonpathogenic remains until humans have been inoculated. For example, the Daker strain of yellow fever produced from infected suckling mouse brains induced encephalitis in 1% of vaccines. Another crucial problem is the possible contamination of the vaccine by exogenous viruses during passages in cell culture or in animals, especially in monkeys. In

25 light of the more recent knowledge of the potential danger of viruses that can be

transmitted from animals to humans, this choice of developing live vaccines is highly questionable.

In contrast to the somewhat haphazard approaches of selecting for live vaccines, discussed above, modern developmental approaches introduce specific mutations into the 5 genome of the pathogen which affects the ability of that pathogen to induce disease. Defined genetic manipulation is the current approach being taken in an attempt to develop live vaccines for various diseases caused by pathogenic microorganisms.

In an effort to develop live vaccines which are safer and elicit a higher immunological response, researchers have focused their efforts to developing live vaccines 10 having specific genetic mutations. Curtiss, in U.S. Patent No. 5,294,441, discloses that *S. typhi* can be attenuated by constructing deletions ( $\Delta$ ) in either or both the *cya* (adenylate cyclase) and *crp* (cyclic 3', 5'-AMP [cAMP] receptor protein) genes. cAMP and the cAMP receptor protein, the products of pleiotropic genes *cya* and *crp*, respectively, function in combination with one another to form a regulatory complex that affects 15 transcription of a large number of genes and operons. Consequently, mutating either of these genes results in an attenuated microorganism. Furthermore, microorganisms having single mutations in either the *cya* or *crp* genes can not supplement their deficiency by scavenging these gene products from a host to be vaccinated. The *crp* gene product is not available in mammalian tissues, and while the metabolite produced by the *cya* gene 20 product, cAMP, is present in mammalian cells, the concentrations present in the cells which *S. typhi* invades are below the concentrations necessary to allow *cya* mutants to exhibit a wild-type phenotype. See, Curtiss, *et al.*, *Infect. Immun.*, 55:3035-3043 (1987).

Since cAMP is present in host tissues at some level, Curtiss *et al.* stabilized the  $\Delta$ ~~Δ~~*cya* microorganisms by introducing a mutation into the *crp* gene. Tacket, *et al.*, *Infect. Immun.*, 60(2):563-541 (1992), conducted a study with healthy adult in-patient volunteers 25

which revealed that attenuated *S. typhi* having deletions in the *cya* and *crp* genes have the propensity to produce fever and bacteremia (bacteria in the blood).

A similar approach in the attempt to develop live vaccines has been taken by Dr. B.A.D. Stocker. The genes mutated by Stocker produce products which are also not available in host tissues. Stocker, in U.S. Patent No. 5,210,035, describes the construction of vaccine strains from pathogenic microorganisms made non-virulent by the introduction of complete and non-reverting mutational blocks in the biosynthesis pathways, causing a requirement for metabolites not available in host tissues. Specifically, Stocker teaches that *S. typhi* may be attenuated by interrupting the pathway for biosynthesis of aromatic (*aro*) metabolites which renders *Salmonella* auxotrophic (i.e., nutritionally dependent) for *p*-aminobenzoic acid (PABA) and 2, 3-dihydroxybenzoate, substances not available to bacteria in mammalian tissue. These *aro*-mutants are unable to synthesize chorismic acid (a precursor of the aromatic compounds PABA and 2, 3-dihydroxybenzoate), and no other pathways in *Salmonella* exist that can overcome this deficiency. As a consequence of this auxotrophy, the *aro*-deleted bacteria are not capable of proliferation within the host; however they reside and grow intracellularly long enough to stimulate protective immune responses. In the technical paper authored by Tacket, *et al.*, discussed above, attenuated strains of *S. typhi* were also constructed for use as vaccines by introducing deletions in the *aroC* and *aroD* genes, according to Stocker. However, these attenuated strains administered to healthy in-patient volunteers have the propensity to produce fever and bacteremia. (Hone *et al.* (1987), Hormaeche *et al.* (1996) *Vaccine* 14:251-259; Hassan and Curtiss (1997) *Avian Dis.* 41:783-791; and Miller *et al.* (1990) *Res. Microbiol.* 141:817-821).

Comparative studies between these vaccines have not been rigorously tested and thus the efficacy of these current strains with respect to each other remains unclear. Moreover, toxicity (e.g., symptoms such as diarrhea) of current live bacterial vaccine

candidates and the reality that many individuals within the human population are immunocompromised clearly warrants the search for additional vaccines that offer better protection, are longer lasting, and have less toxicity.

Another significant problem with vaccine development is the fact that many 5 pathogenic species are comprised of multiple serotypes that can cause disease in animal hosts vaccinated against a similar pathogenic strain. Previous attempts at developing a long-term cross-protective *Salmonella* vaccine have often been problematic. For example, live attenuated *aroA* *Salmonella* strains have been shown to elicit a cross-protective response against heterologous serotypes (e.g., group B (*typhimurium*) and Group D 10 (*enteritidis* and *dublin*)) strains, but the cross-protective capacity is virtually eliminated after the vaccine is cleared from the immunized animals. Hormaeche et al. (1996).

Like many cellular macromolecules, DNA is subject to postsynthetic 15 "modification" by addition of small chemical moieties to the intact polymer. In a variety of organisms this involves enzymatic addition of methyl (-CH<sub>3</sub>) groups to DNA, either at position C5 of cytosine or at position N6 of adenine, shown in Figure 2. The enzymes responsible for the addition of methyl groups to DNA are known as DNA methyltransferases or DNA methylases. DNA methylases can be divided into two classes: (1) those that methylate cytosine (DNA cytosine methylases); and (2) those that methylate adenine (DNA adenine methylases).

20 Methylation at adenine residues by DNA adenine methylase (Dam) controls the timing and targeting of important biological processes such as DNA replication, methyl-directed mismatch repair, and transposition (Marinus, *E. coli and Salmonella: Cellular and Molecular biology*, 2nd ed., 782-791 (1996)). In addition, in *E. coli*, Dam regulates the expression of operons such as pyelonephritis-associated pili (*pap*) which are an important 25 virulence determinant in upper urinary tract infections (Roberts, et al., *J. Urol.*, 133:1068-1075 (1985)); van der Woude, et al., *Trends Microbiol.*, 4:5-9 (1996). The latter regulatory

mechanism involves formation of heritable DNA methylation patterns, which control gene expression by modulating the binding of regulatory proteins.

There remains a serious need for vaccines that are prepared from live, pathogenic microorganisms which are safe and when administered to a host and will induce an 5 effective type of immune response in the host. It is also very desirable to develop a single vaccine strain that is capable of stimulating an immune response against a different strain (i.e., heterologous serotypes or species). There is also a further need for safe and effective antimicrobial drugs that may be used to treat patients afflicted by disease caused by pathogenic microorganisms.

10 All references and patent applications cited within this application are herein incorporated by reference in their entirety.

#### SUMMARY OF THE INVENTION

15 This invention based on the discoveries that DNA adenine methylase (Dam) is essential for *Salmonella* pathogenesis and that Dam<sup>+</sup> *Salmonella* are effective as live attenuated vaccines against murine typhoid fever and elicit an immune response against a second species of *Salmonella*. Since DNA adenine methylases are highly conserved in many pathogenic bacteria that cause significant morbidity and mortality, Dam derivatives 20 of these pathogens may be effective as live attenuated vaccines. Moreover, since methylation of DNA adenine residues is essential for bacterial virulence, drugs that alter the expression of or inhibit the activity of DNA adenine methylases are likely to have broad antimicrobial action and thus genes that encode DNA adenine methylases and their products are promising targets for antimicrobial drug development.

Accordingly, it is an object of this invention to provide live vaccines for vaccinating a host against a pathogenic microorganism or a spectrum of similar pathogenic microorganisms.

It is a further object of this invention to provide live vaccines which serve as 5 carriers for antigens, preferably immunogens of other pathogens, particularly microorganisms, including viruses, prokaryotes, and eukaryotes.

It is yet another object of this invention to provide antimicrobial drugs that specifically inhibit DNA adenine methylases and the genes responsible for the production of DNA adenine methylases. Furthermore, the compositions of the present invention 10 comprise natural and synthetic molecules having inhibitory effects on (i) DNA adenine methylase enzymatic activities, (ii) expression of DNA adenine methylases, (iii) DNA adenine methylase activators, (iv) activating compounds for DNA adenine methylase repressors, and/or (v) virulence factors that are regulated by DNA adenine methylases.

Accordingly, in one aspect the invention provides immunogenic compositions 15 comprising live attenuated pathogenic bacteria in a pharmaceutically acceptable excipient, said pathogenic bacteria containing a mutation which alters DNA adenine methylase (Dam) activity such that the pathogenic bacteria are attenuated.

In another aspect, the invention provides immunogenic compositions comprising killed pathogenic bacteria in a pharmaceutically acceptable excipient, said pathogenic 20 bacteria containing a mutation which alters DNA adenine methylase (Dam) activity.

In another aspect, the invention provides attenuated strains of pathogenic bacteria, said bacteria containing a mutation which alters Dam activity such that the bacteria are attenuated.

In another aspect, the invention provides methods of eliciting an immune response 25 in an individual comprising administering which entail administering any of the

compositions described herein to the individual in an amount sufficient to elicit an immune response.

In another aspect, the invention provides methods of preventing infection by pathogenic bacteria in an individual, comprising administering any of the immunogenic compositions described herein to the individual in an amount sufficient to reduce a symptom associated with infection by the pathogenic bacteria upon infection by the pathogenic bacteria.

In another aspect, the invention provides methods of treating a pathogenic bacterial infection in an individual, comprising administering any of the immunogenic compositions described herein to the individual in an amount sufficient to reduce a symptom associated with infection by the pathogenic bacteria in the individual.

In another aspect, the invention provides methods of treating an individual infected with a pathogenic bacteria, comprising administering to the individual a composition comprising an agent which alters Dam activity.

In another aspect, the invention provides methods of eliciting an immune response against a second species of *Salmonella* in an individual, comprising administering to the individual an immunogenic composition comprising an attenuated first species of *Salmonella*, said first species containing a mutation which alters Dam activity such that the *Salmonella* is attenuated.

In another aspect, the invention also provides screening methods. The invention includes methods of identifying an agent which may have anti-bacterial activity comprising using an in vitro transcription system to detect an agent which alters the level of transcription from a *dam* gene when the agent is added to the in vitro transcription system, wherein an agent is identified by its ability to alter the level of transcription from the *dam* gene as compared to the level of transcription when no agent is added.

In another aspect, the invention provides methods of identifying an agent which may have anti-bacterial activity comprising using an in vitro translation system to detect an agent which alters the level of translation from an RNA transcript encoding Dam when the agent is added to the in vitro transcription system, wherein an agent is identified by its 5 ability to alter the level of translation from the RNA transcript encoding Dam as compared to the level of translation when no agent is added.

In another aspect, the invention provides methods of identifying an agent which may have anti-bacterial activity comprising determining whether the agent binds to Dam, wherein an agent is identified by its ability to bind to Dam.

10 In another aspect, the invention provides methods of identifying an agent which may have anti-bacterial activity comprising the steps of: (a) incubating non-methylated oligonucleotides comprising a Dam binding site with Dam, S-adenosylmethionine, and an agent, wherein said nonmethylated oligonucleotide further comprises a signal; (b) digesting all nonmethylated target sites, thereby releasing said nonmethylated 15 oligonucleotides; and (c) detecting inhibition of DNA adenine methylase as an increase in said signal due to digestion of said nonmethylated target sites, wherein an agent is identified by its ability to cause an increase in signal compared to conducting steps (a), (b), and (c) in absence of agent.

20 In another aspect, the invention provides methods of identifying an agent which may have anti-bacterial activity comprising the steps of: (a) contacting an agent to be tested with a suitable host cell that has Dam function; and (b) analyzing at least one characteristic which is associated with alteration of Dam function, wherein an agent is identified by its ability to elicit at least one said characteristic.

25 The invention also provides methods of preparing the vaccines and strains described herein. In one aspect, the invention provides methods of preparing the immunogenic compositions described herein, comprising combining a pharmaceutically excipient with

pathogenic bacteria containing a mutation which alters DNA adenine methylase (Dam) activity such that the pathogenic bacteria are attenuated.

In another aspect, the invention provides methods for preparing attenuated bacteria capable of eliciting an immunological response by a host susceptible to disease caused by 5 the corresponding or similar pathogenic microorganism comprising constructing at least one mutation in said pathogenic bacteria wherein a first mutation results in altered Dam function.

Another object of this invention is to provide a method whereby a vaccine may be produced by altering the expression of a global regulator of virulence genes and, more 10 specifically, by altering the expression of DNA adenine methylases.

Another object of this invention is to provide a method whereby a vaccine may be produced by altering the expression of genes regulated by DNA adenine methylases.

In another aspect, the invention provides methods for preparing a live vaccine from a virulent pathogenic bacteria, such as *Salmonella*, comprising altering the expression of 15 DNA adenine methylases and/or the expression of genes that are regulated by DNA adenine methylases in a virulent strain of a pathogenic bacteria that is, or is similar to, the microorganism desired to be vaccinated against.

It is yet a further object of this invention to provide a method of treating a host, such as a vertebrate infected with a pathogen by administering to the vertebrate a compound or 20 compounds that alter the expression of or inhibit the activity of DNA adenine methylases.

Additional objects, advantages and novel features of this invention shall be set forth in part in the description that follows, and in part will become apparent to those skilled in the art upon examination of the following specification or may be learned by the practice of the invention. The objects and advantages of the invention may be realized and attained by 25 means of the instrumentalities, combinations, compositions, and methods particularly pointed out in the appended claims.

## BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings, which are incorporated herein and form a part of the specification, assist in illustrating the present invention and, together with the description, serve to explain the principles of the invention. The accompanying drawings are not drawn 5 to scale.

Figure 1 is a graphic representation of the levels of antibody present following the primary and secondary immune responses.

Figure 2 is a schematic representation of the sites of methylation that occur on cytosine and adenine.

10 Figure 3 is a graphic representation illustrating that Dam regulates *in vivo* induced genes.  $\beta$ -galactosidase expression from *S. typhimurium* ivi fusions in Dam<sup>+</sup> and Dam<sup>-</sup> strains grown in LB. The vertical axis shows  $\beta$ -galactosidase activities ( $\mu$ -moles of o-nitrophenol (ONP) formed per minute per A<sub>600</sub> unit per milliliter of cell suspension  $\times 10^3$ ).

15 Figure 4 is a graphic representation illustrating that Dam represses PhoP activated genes.  $\beta$ -galactosidase expression from *S. typhimurium* ivi fusions grown in minimal medium. The vertical axis shows  $\beta$ -galactosidase activities ( $\mu$ -moles of o-nitrophenol (ONP) formed per minute per A<sub>600</sub> unit per milliliter of cell suspension  $\times 10^3$ ). The *dam* genotype is shown below the horizontal axis, and the *phoP* genotype is shown as black (PhoP<sup>+</sup>) and gray (PhoP<sup>-</sup>) boxes.

20 Figure 5 shows that PhoP affects the formation of *Salmonella* DNA methylation patterns. DNA methylation patterns formed in PhoP<sup>+</sup> and PhoP<sup>-</sup> strains grown in minimal medium. The arrows depict DNA fragments that are present in PhoP<sup>-</sup> *Salmonella* but are absent in PhoP<sup>+</sup> *Salmonella*.

25 Figure 6 are graphs depicting the amount and tissue distribution of *Salmonella* in mice immunized with Dam<sup>-</sup> mutants (solid boxes) or not immunized (open boxes) on day 1

and day 5. PP, Peyer's patches; MLN, mesenteric lymph nodes; CFU, colony forming units.

Figure 7 are graphs depicting amount and tissue distribution of *Salmonella* in mice immunized with Dam<sup>-</sup> mutants (solid boxes) or not immunized (open boxes) on day 1, 5, 5 14 and 28. PP, Peyer's patches; MLN, mesenteric lymph nodes; CFU, colony forming units.

Figures 8 (A) - (C) are half-tone reproductions of 2D gel electrophoresis of whole-cell protein abstracts of *S. typhimurium* showing proteins produced in Dam<sup>-</sup> strain (*dam* non-polar deletion, MT2188; (A)); Dam<sup>+</sup> strain (wild type, ATCC 14028 (B)); and Dam<sup>+++</sup> 10 strain (overproducer, MT2128).

#### DETAILED DESCRIPTION

We have discovered that the *dam* gene and its product enzyme DNA adenine methylase (Dam) are required for bacterial virulence. Despite previous research efforts directed to Dam functions, the critical role of Dam in bacterial virulence, the inventive 15 implications of this role, as well as the ability of a Dam<sup>-</sup> mutant vaccine to elicit a protective immune response, have not been reported. Previously, all reported *dam* mutations from other laboratories used *Salmonella* strain LT2 which is at least 1000-fold less virulent than the wild type when delivered intraperitoneally. Equipped with the knowledge of this discovery, the present invention is directed towards (a) vaccines having 20 non-reverting genetic mutations in either (i) genes that would alter a function, such as expression, of DNA adenine methylases and/or (ii) genes that are regulated by DNA adenine methylases; (b) a class of inhibitors that are natural and/or synthetic molecules having binding specificity for (i) DNA adenine methylases and/or genes that encode DNA adenine methylases, (ii) activators of DNA adenine methylases and/or activating 25 compounds for repressors of DNA adenine methylases, and (iii) virulence factors that are regulated by Dam; (c) methods for preparing vaccines and inhibitors based on the

knowledge that DNA adenine methylase is essential for bacterial pathogenesis; (d) methods of eliciting an immune response using the immunogenic compositions described herein; (e) methods for treating vertebrates with (i) the vaccines of the present invention prior to their becoming infected or (ii) the inhibitors of the present invention after their becoming 5 infected with a pathogenic microorganism; (f) methods of preventing infection using the immunogenic compositions described herein; and (g) screening methods to identify compounds which may be useful therapeutic agents.

As described in the Examples, the oral lethal dose of a Dam<sup>-</sup> mutant (created by an insertion in the *dam* gene (Mud-Cm)) in *S. typhimurium* required to kill 50% of the animals 10 (LD<sub>50</sub>) was increased over 10,000-fold and the intraperitoneal (i.p.) LD<sub>50</sub> was increased over 1,000 fold compared to wild type (Example 1; Table 1). Further, the highly attenuated Dam<sup>-</sup> mutants were found to confer a protective immune response in an art-accepted model of murine typhoid fever (Example 2; Table 2). All 17 mice immunized with a *S. typhimurium* Dam<sup>-</sup> insertion strain survived a wild-type challenge of 10<sup>4</sup> above the LD<sub>50</sub>, 15 whereas all 12 nonimmunized mice died following challenge. Survival studies comparing Dam<sup>+</sup> to Dam<sup>-</sup> *Salmonella* showed that Dam<sup>-</sup> bacteria were fully proficient in colonization of a mucosal site (Peyer's patches) but showed severe defects in colonization of deeper tissue sites (Example 2; Figure 6). Without wishing to be bound by theory, the inventors note that one possible explanation of why Dam<sup>-</sup> elicits protective immune response is 20 because the mutant bacteria grow in intestinal mucosa long enough to elicit an immune response but are unable to invade and/or colonize deeper tissue.

Even more striking, especially in view of the widely held tenet in the art that a vaccine containing one species of *Salmonella* could not elicit an immune response against a second species of *Salmonella*, or at least a significant, lasting immune response against a 25 second strain, especially if the species is attenuated due to mutation in a single gene, our data show such cross-protection. Mice immunized with Dam<sup>-</sup> *S. typhimurium* (serogroup

B) were protected against a heterologous challenge (100 to 1000 LD<sub>50</sub>) with *S. enteritidis* and *S. dublin* (serogroup D) eleven weeks post immunization (Example 3; Table 3). This protection persisted more than six weeks after the vaccine strain was cleared from the immunized animals (i.e., more than six weeks after the Dam<sup>-</sup> organisms could not be

5 detected in Peyer's patches, mesenteric lymph nodes, liver and spleen). In contrast to the *Salmonella* cross-protection, no protection was observed against *Yersinia pseudotuberculosis* five weeks post immunization. Similarly, immunization with Dam<sup>-</sup> *S. enteritidis* conferred cross-protection against *S. typhimurium* and *S. dublin*. Although live attenuated *Salmonella* strains have been shown to elicit cross-protection between group B

10 (typhimurium) and group D (*enteritidis* and *dublin*) strains (attributed to a shared common LPS antigenic determinant), the cross-protective response is very short-lived, and is virtually eliminated ten to twelve weeks post immunization. Hormaeche et al. (1996) *Vaccine* 251-259.

The ectopic expression in Dam derivatives (i.e., expression of proteins that are

15 normally repressed) as described in Examples 1 and 3 has broad applications to vaccine development. Ectopic expression in Dam derivatives of many pathogens may yield protective and/or cross-protective responses to the parent virulent organisms. *Salmonella* Dam derivatives may have utility as a platform to express passenger bacterial and viral antigens that elicit strong protective immune responses against the cognate pathogen.

20 Since Dam<sup>-</sup> immunized mice can clear a lethal bacterial load of fully-virulent *Salmonella* organisms, Dam<sup>-</sup> vaccines may have therapeutic utility to effectively treat a pre-existing infection. Since Dam<sup>-</sup> derivatives ectopically express multiple proteins, it opens the possibility that vaccines could be constructed in strains that are less harmful to humans, which would exploit the benefits of the high levels of protection elicited by live vaccines

25 while reducing the risk of infection to immunocompromised individuals.

The fact that DNA adenine methylase is essential for bacterial pathogenesis, in, for example, *Salmonella* is also of extreme importance, the implications of which are many. First, the *dam* gene is highly conserved in pathogenic bacteria, that is, the gene sequence of *dam* in one microorganism shares sequence identity with the *dam* gene in another

5 microorganism not only within the same species but also across bacterial genera; and second, the *dam* gene regulates many genes involved in virulence. Since DNA adenine methylases are highly conserved in many pathogenic bacteria that cause significant morbidity and mortality, such as *Vibrio cholerae* (Bandyopadhyay and Das, *Gene*, 140:67-71 (1994), *Salmonella typhi* (1999-3, Sanger Centre), pathogenic *E. coli* (Blattner, *et al.*,

10 *Science*, 277:1453-1474 (1997), *Yersinia pestis* (1999-3, Sanger Centre), *Haemophilus influenzae* (Fleischmann, *et al.*, *Science*, 269:496-512 (1995), and *Treponema pallidum* (Fraser, *et al.*, *Science*, 281:375-388 (1998))), Dam derivatives of these pathogens may be effective as live attenuated vaccines. Moreover, since Dam is essential for bacterial virulence, Dam inhibitors are likely to have broad antimicrobial action and thus Dam or

15 any gene that alters the expression of Dam is a promising target for antimicrobial drug development.

The implications of this are as follows: (1) it is now possible to rationally develop a class of inhibitors that are natural and/or synthetic molecules having binding specificity for (i) DNA adenine methylases and/or the *dam* gene, (ii) Dam activators and/or activating compounds for Dam repressors, and (iii) virulence factors that are regulated by Dam; and (2) it is now possible to produce vaccines having non-reverting genetic mutations in either (i) genes that would alter the expression of DNA adenine methylases and/or (ii) virulence genes that are regulated by DNA adenine methylases. Because Dam is a global regulator of gene expression and many of these regulated genes are conserved in various species and genera, it is highly probable that inhibitors and vaccines based on DNA adenine methylase will give cross-protection. Thus, as discussed above, an inhibitor or a vaccine against one

strain, species, serotype and/or group of pathogen would provide protection against a different strain of pathogen.

Compositions described herein may be used for administration to individuals. They may be administered, for example, for experimental purposes, or to obtain a source of anti-  
5 bacteria antibody, such as *Salmonella* antibody. They may also be administered to elicit an immune response in an individual as well as to protect an individual from infection or to treat an individual infected with a virulent bacteria, such as *Salmonella*.

### ***General techniques***

The practice of the present invention will employ, unless otherwise indicated,  
10 conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry and immunology, which are within the skill of the art. Such techniques are explained fully in the literature, such as, *Molecular Cloning: A Laboratory Manual*, second edition (Sambrook et al., 1989); *Oligonucleotide Synthesis* (M.J. Gait, ed., 1984); *Animal Cell Culture* (R.I. Freshney, ed., 1987); *Methods in Enzymology* (Academic Press, Inc.); *Handbook of Experimental Immunology* (D.M. Wei & C.C. Blackwell, eds.); *Gene Transfer Vectors for Mammalian Cells* (J.M. Miller & M.P. Calos, eds., 1987); *Current Protocols in Molecular Biology* (F.M. Ausubel et al., eds., 1987); *PCR: The Polymerase Chain Reaction* (Mullis et al., eds., 1994); *Current Protocols in Immunology* (J.E. Coligan et al., eds., 1991); *Short Protocols in Molecular Biology* (Wiley & Sons, 1999).

### ***Definitions***

“DNA adenine methylases” (Dam) are defined as a group of enzymes which are able to methylate adenine residues in DNA. *Dam* genes and Dam products encoded by  
25 *dam* genes are known in the art, and the definition includes Dam enzymes that share

significant amino acid similarity to the DNA adenine methylase from *E. coli* (gi 118682) and *Salmonella* (gi 2500157) and that preferentially methylate the sequence “GATC” on DNA, methylating the N-6 position of adenine. Particular highly conserved DNA sequences encoding a region of Dam are depicted in SEQ ID NOS:1-4, as described herein.

5 In accordance with art-accepted designations, “*dam*” or “*dam gene*” indicates a gene encoding a DNA adenine methylase, and “Dam” indicates a DNA adenine methylase (i.e., the polypeptide). For purposes of the present invention a gene is defined as encompassing the coding regions and/or the regulatory regions.

Dam “activity” or “function” means any bio-activity associated with *dam* expression or non-expression. Dam activities are described herein. For example, non-expression of *dam* leads to repression (or, alternatively, de-repression) of certain genes regulated by Dam; thus, repression (or de-repression) of any of these genes is a Dam activity. As another example, methylation of adenine in DNA (for example, methylation of GATC) is an activity associated with *dam* expression and the resultant Dam product; thus, 15 adenine methylation is a Dam activity. Dam “activity” or “function” thus encompasses any one or more bio-activities associated with *dam* expression.

An “alteration” of Dam activity is any change in any Dam activity, as compared to wild-type Dam function. An “alteration” may or may not be a complete loss of a Dam activity, and includes an increase or decrease of a Dam activity. Bacteria which contain a 20 mutation that alters Dam activity are generally referred to as “Dam derivatives.”

“Expression” includes transcription and/or translation, as well as any factor or event which affects expression (such as an upstream event, such as a second gene which affects expression).

A “vaccine” is a pharmaceutical composition for human or animal use, particularly 25 an immunogenic composition which is administered with the intention of conferring the recipient with a degree of specific immunological reactivity against a particular target, or

group of targets (i.e., elicit and/or enhance an immune response against a particular target or group of targets). The immunological reactivity, or response, may be antibodies or cells (particularly B cells, plasma cells, T helper cells, and cytotoxic T lymphocytes, and their precursors) that are immunologically reactive against the target, or any combination thereof. For purposes of this invention, the target is primarily a virulent bacteria, such as *Salmonella*. In instances where an attenuated bacteria is used as a carrier, the target may be another antigen as described herein. The immunological reactivity may be desired for experimental purposes, for treatment of a particular condition, for the elimination of a particular substance, and/or for prophylaxis.

“Pathogenic” bacteria are bacteria that are capable of causing disease. “Virulence” is a indicator of the degree of pathogenicity which may be numerically expressed as the ratio of the number of cases of overt infection to total number infected. It is understood that the pathogenic bacteria used in the vaccines described herein are other than innocuous strains commonly used in laboratories, and are known to and/or are capable of causing disease.

“Attenuated” bacteria used in the compositions described herein are bacteria which exhibit reduced virulence. As is well understood in the art, and described above, virulence is the degree to which bacteria are able to cause disease in a given population. For purposes of the invention, attenuated bacteria have virulence reduced to a suitable and acceptable safety level, as is generally dictated by appropriate government agencies. The degree of attenuation which is acceptable depends on, *inter alia*, the recipient (i.e., human or non-human) as well as various regulations and standards which are provided by regulatory agencies such as the U.S. Food and Drug Administration (FDA). Most preferably, especially for human use, attenuated bacteria are avirulent, meaning that administration of these organisms cause no disease symptoms. As is well understood in the art, attenuated bacteria are alive, at least at the time of administration.

“Antigen” means a substance that is recognized and bound specifically by an antibody or by a T cell antigen receptor. As is well understood in the art, antigens can include peptides, proteins, glycoproteins, polysaccharides, gangliosides and lipids, as well as portions and/or combinations thereof. Antigens can be those found in nature or can be 5 synthetic.

An “adjuvant” is a chemical or biological agent given in combination with an attenuated bacteria as described herein to enhance its immunogenicity. As is known in the art, an “adjuvant” is a substance which, when added to an antigen, nonspecifically enhances or potentiates an immune response to the antigen in the recipient (host).

10 “Stimulating”, “eliciting”, or “provoking” an immune response (which can be a B and/or T cell response) means an increase in the response, which can arise from eliciting and/or enhancement of a response.

15 “Heterologous” means derived from and/or different from an entity to which it is being compared. For example, a “heterologous” antigen with respect to a bacterial strain is an antigen which is not normally or naturally associated with that strain.

An “effective amount” is an amount sufficient to effect a beneficial or desired result including a clinical result, and as such, an “effective amount” depends on the context in which it is being applied. An effective amount can be administered in one or more doses. For purposes of this invention, an effective amount of Dam derivative bacteria (or a 20 composition containing Dam derivative bacteria) is an amount that induces an immune response. In terms of treatment, an effective amount is amount that is sufficient to palliate, ameliorate, stabilize, reverse or slow the progression of a bacterial disease, or otherwise reduce the pathological consequences of the disease. In terms of prevention, an effective amount is an amount sufficient to reduce (or even eliminate) one or more symptoms upon 25 exposure and infection.

“Treatment” is an approach for obtaining beneficial or desired clinical results.

Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, amelioration or palliation of the disease state.

5 “Preventing” disease or infection means a reduction (including, but not limited to, elimination) of one or more symptoms of infection in an individual receiving a composition described herein as compared to otherwise same conditions except for receiving the composition(s). As understood in the art, “prevention” of infection can include milder 10 symptoms and does not necessarily mean elimination of symptoms associated with infection.

An “individual”, used interchangeably with “host”, is a vertebrate, preferably a mammal, more preferably a human. Mammals include, but are not limited to, farm animals (such as cattle), sport animals, and pets. An “individual” also includes fowl, such as 15 chickens. A “host” may or may not have been infected with a bacteria.

An “agent” means a biological or chemical compound such as a simple or complex organic or inorganic molecule, a polypeptide, a polynucleotide, carbohydrate or lipoprotein. As vast array of compounds can be synthesized, for example oligomers, such as oligopeptides and oligonucleotides, and synthetic organic compounds based on various 20 core structures, and these are also included in the term “agent”. In addition, various natural sources can provide compounds for screening, such as plant or animal extracts, and the like. Compounds can be tested singly or in combination with one another.

“Anti-bacterial activity” or “controlling virulence” means that an agent may negatively affect the ability of bacteria to cause disease. For purposes of the invention, an 25 agent which may control virulence is one which alters Dam activity, and may be selected

by the screening methods described herein, and further may, upon further study, prove to control bacterial virulence and may even exert therapeutic activity.

“Comprising” and its cognates mean “including”.

“A”, “an” and “the” include plural references, unless otherwise indicated. For 5 example, “a” Dam means any one or more DNA adenine methylases.

### *Compositions of the invention*

The compositions described are useful for eliciting an immune response, and/or treating or preventing disease associated with bacterial infection, especially *Salmonella* 10 infection. Vaccines prepared from live, pathogenic bacteria are provided for the immunization or for the treatment of a host which is susceptible to disease caused by the corresponding pathogenic bacteria, by a similar pathogenic bacteria of the same strain, species, serotype, and/or group, or by a different bacteria of a different strain, species, serotype, and/or group. The live vaccines produced herein may also serve as carriers for 15 antigens, such as immunogens of other pathogens thereby producing a multiple immunogenic response.

Accordingly, in one embodiment, the invention provides an immunogenic composition comprising live attenuated pathogenic bacteria, such as *Salmonella*, and a pharmaceutically acceptable excipient, said pathogenic bacteria containing (having) a 20 mutation which alters DNA adenine methylase (Dam) activity such that the pathogenic bacteria are attenuated. In some embodiments, the mutation is in a gene encoding a DNA adenine methylase (Dam), wherein the mutation alters DNA adenine methylase activity.

Dam activity may be increased or decreased, and Dam activity may be altered on any level, including transcription and/or translation. With respect to translation, for 25 example, activity can be altered in any number of ways, including the amount of protein produced and/or that nature (i.e., structure) of the protein produced. For example, a

mutation could result in increasing or reducing the amount of Dam produced by the cell (due to affecting transcriptional and/or post-transcriptional events); alternatively, a mutation could give rise to an altered Dam with altered activity. Generating mutations and mutants which alter Dam activity use techniques well known in the art. As an example,

5 Dam production could be lowered by using a promoter which is known to initiate transcription at a lower level. Assays to determine level of transcription from a given transcriptional regulatory element such as a promoter are well known in the art. The native *dam* promoter could be replaced with a promoter of lower transcriptional activity; alternatively, a *dam* (in which native *dam* gene has been removed) could be used as a basis

10 for integrating a re-engineered *dam* gene containing a lower activity promoter to integrate into the genome. Alternatively, a different *dam* gene could be used such as a T4 *dam*. An example of a *dam* over-producer, a pTP166 plasmid that produces *E. coli* Dam at 100-fold wild-type level could be used. Mutations can be within the *Dam* gene itself (including transcriptional and/or translational regulatory elements) as well as a gene or genes which

15 affect Dam production and/or activity.

Any pathogenic, preferably virulent, strain of bacteria may be used in the immunogenic compositions described herein. In some embodiments, pathogenic bacteria other than *E. coli* are used. In other embodiments, pathogenic *Escherichia* is used, preferably *E. coli*. Because overexpression of *dam* can lead to a useful vaccine, *dam* gene may or may not be essential, i.e., deletion of *dam* may or may not be lethal.

The subject invention is particularly applicable to a wide variety of *Salmonella*, including any of the known groups, species or strains, more preferably groups A, B, or D, which includes most species which are specific pathogens of particular vertebrate hosts. Illustrative of the *Salmonella*-causing disease for which live vaccines can be produced are

20 *S. typhimurium*; *S. enteritidis*, *S. typhi*; *S. abortus-ovi*; *S. abortus-equii*; *S. dublin*; *S.*

*gallinarum*; *S. pullorum*; as well as others which are known or may be discovered to cause infections in mammals.

Other organisms for which the subject invention may also be employed include *Yersinia spp.*, particularly *Y. pestis*, *Vibrio spp.*, particularly *V. cholerae*, *Shigella spp.*, particularly *S. flexneri* and *S. sonnei*; *Haemophilus spp.*, particularly *H. influenzae*, more particularly type b; *Bordetella*, particularly *B. pertussis*; *Neisseria*, particularly *N. meningitidis* and *N. gonorrhoeae*; *Pasteurella*, particularly *P. multocida*, pathogenic *E. coli*, and *Treponema* such as *T. pallidum*; as well as others which are known or may be discovered to cause infections in mammals.

10 In another embodiment, the invention provides vaccines used to vaccinate a host comprising a pharmaceutically acceptable excipient and an attenuated form of a pathogenic bacteria, wherein attenuation is attributable to at least one mutation, wherein a first mutation alters either (i) the expression of or the activity of one or more DNA adenine methylases or (ii) the expression of one or more genes regulated by a DNA adenine methylase. The first mutation is preferably non-reverting, and in some embodiments is constructed in a gene whose product activates one or more of said DNA adenine methylases. The first mutation may be constructed in a gene whose product inactivates or decreases the activity of one or more of said DNA adenine methylases. In other embodiments, the first mutation is constructed in a gene whose product represses the expression of said DNA adenine methylases, and the gene product may repress Dam. The vaccine may further comprise a second mutation independent of said first mutation with the second mutation resulting in an attenuated microorganism. The second mutation is preferably non-reverting.

15 20

In another embodiment, the invention provides vaccines for provoking an immunological response in a host to be vaccinated comprising a bacterial cell having a

mutation, introduced into a gene that disables the ability of said bacterial cell to regulate the expression of a DNA adenine methylase (Dam), which is expressed by the *dam* gene.

The ectopic expression of multiple proteins in Dam<sup>-</sup> vaccines suggests the possibility that killed Dam<sup>-</sup> organisms may elicit significantly stronger protective immune responses than killed Dam<sup>+</sup> organisms. Accordingly, in some embodiments, the invention provides immunogenic compositions comprising killed pathogenic bacteria which contain a mutation which alters Dam activity and a pharmaceutically acceptable excipient. Preferably, the mutation is in the *dam* gene, and, as described herein, may result in reduction or increase in Dam activity. In some embodiments, the *dam* mutation causes death of the bacteria. In other embodiments, the mutation is attenuating, and the bacteria are killed by using methods well known in the art, such as sodium azide treatment and/or exposure to UV. In the instance where the mutation is lethal, the bacteria may further be treated for killing (e.g., using sodium azide and/or UV). Examples of bacteria suitable for these vaccines include, but are not limited to, *Salmonella*, *Vibrio* (including *V. cholerae*) and *Yersinia* (including *Y. pseudotuberculosis*).

Preferably, the compositions comprise a pharmaceutically acceptable excipient. A pharmaceutically acceptable excipient is a relatively inert substance that facilitates administration of a pharmacologically effective substance. For example, an excipient can give form or consistency to the vaccine composition, or act as a diluent. Suitable excipients include but are not limited to stabilizing agents, wetting and emulsifying agents, salts for varying osmolarity, encapsulating agents, buffers, and skin penetration enhancers. Examples of pharmaceutically acceptable excipients are described in Remington's Pharmaceutical Sciences (Alfonso R. Gennaro, ed., 19th edition, 1995).

The invention also comprises immunogenic compositions containing any combination of the mutant strains described herein (whether attenuated or killed), for a given genus, such as *Salmonella*. Since the two different vaccine strains (such as a Dam<sup>-</sup>

and a Dam overproducer) may produce two different repertoires of potentially protective antigens, use of them in combination may elicit a superior immune response.

Pathogenic bacteria, according to this invention, are made attenuated, preferably avirulent, as a result of a non-reverting mutation that is created in at least one gene, which 5 thereby alters the a function of a DNA adenine methylase(s). Essentially, the live vaccines provided for, according to the preferred embodiment of the present invention, originate with a pathogenic bacteria. A non-reverting mutation is introduced into a gene of the pathogen, thus altering the expression of DNA adenine methylases. "Non-reverting" mutations generally revert in less than about 1 in  $10^8$ , preferably less than about 1 in  $10^{10}$ , 10 or preferably less than about 1 in  $10^{15}$ , even more preferably less than 1 in  $10^{20}$  cell divisions. Preferably, the mutation is non-leaky; however, regulation of genes by Dam appears to be exquisitely sensitive to Dam concentration. Therefore, over-expression of 15 Dam as well as under expression of Dam results in the attenuation of the pathogen. The mutation is preferably made in the *dam* gene itself, however it is contemplated in other embodiments of the present invention, discussed in further detail below, that the vaccines according to the present invention may be produced by mutating a related gene or genes either "upstream" or "downstream" of *dam* whose product(s) activate(s) or repress(es) the *dam* gene or, in the alternative, a mutation is constructed in at least one virulence gene that is regulated by DNA adenine methylase. The mutation is non-reverting because restoration 20 of normal gene function can occur only by random coincidental occurrence of more than one event, each such event being very infrequent. For example, Dam methylase activity can be down-regulated and/or shut off by introduction of deletions in the promoter or coding region, insertion of transposons or intervening DNA sequences into the promoter or coding regions, use of an antisense oligonucleotide that blocks expression of the *dam* gene, 25 or use of a ribozyme that prevents *dam* gene expression. Alternatively, the mutation(s) can be an insertion and/or a deletion to an extent sufficient to cause non-reversion.

In the case of a deletion mutation, restoration of genetic information would require many coincidental random nucleotide insertions, in tandem, to restore the lost genetic information. In the case of an insertion plus inversion, restoration of gene function would require coincidence of precise deletion of the inserted sequence and precise re-inversion of 5 the adjacent inverted sequence, each of these events having an exceedingly minute, undetectably low, frequency of occurrence. Thus, each of the two sorts of "non-reverting" mutations has a substantially zero probability of reverting to prototrophy.

Other methods of constructing an insertion in the *Dam* gene would be well known and obvious to one skilled in the art.

10 While a single non-reverting mutation provides a high degree of security against possible reversion to virulence, there still remain events which, while unlikely, have a finite probability of occurrence. Opportunities for reversion exist where microorganisms exist in the host which may transfer by conjugation the genetic capability to the non-virulent organism. Alternatively, there may be a cryptic alternative pathway for the production of 15 DNA adenine methylases which by rare mutation or under stress could become operative. Accordingly, in some embodiments, the attenuated bacteria described herein further comprise a second mutation. Live vaccines with two separate and unrelated mutations should be viable and reasonably long lived in the host, provide a strong immune response upon administration to the host, and they may also serve as a carrier for antigens, such as 20 antigens of other pathogens, of other pathogens to provide immune protection from such pathogens.

Examples of *Salmonella typhimurium* attenuating mutations that may serve as secondary mutations for live attenuated vaccine candidates are *galE* (galactose induced toxicity), *pur* and *aro* (aromatic compounds not available *in vivo*), *crp* and *cya* (global 25 changes in gene expression via catabolite control), and *phoP* (global changes in virulence gene expression) (Hone, *et al.* (1987), Hormaeche, *et al.* (1996); Hassan and Curtiss

(1997); and Miller, *et al.* (1990)). Comparative studies between these vaccines have not been rigorously tested and thus the efficacy of these current strains with respect to each other remains unclear. Moreover, toxicity (e.g., symptoms such as diarrhea) of current live bacterial vaccine candidates and the reality that many individuals within the human 5 population are immunocompromised clearly warrants the search for additional vaccines that offer better protection, are longer lasting, and have less toxicity.

In addition to the mutations discussed above, it is desirable that the bacteria for use as a live vaccine have one or more genetic "marker characters" making it easily 10 distinguishable from other bacteria of the same species, either wild strains or other live vaccine strains. Accordingly, one chooses a strain of the pathogen which desirably has a marker for distinguishing the *Dam*<sup>-</sup> mutant to be produced from other members of the strain. Alternatively, such a marker can be introduced into the vaccine strain. Various 15 markers can be employed, as discussed previously. The marker(s) used should not affect the immunogenic character of the bacteria, nor should it interfere with the processing of the bacteria to produce the live vaccine. The marker will only alter the phenotype, to allow for 20 recognition of the subject bacteria. For example, *Dam* mutants are sensitive to the base analog 2-amino purine (Miller, "Experiments in Molecular Genetics" CSHL 1972). Since the *dam* gene is genetically linked to *cysG*, one can use a pool of transposon insertions to transduce a *cysG*<sup>-</sup> recipient to *cysG*<sup>+</sup>. These prototrophs are screened for 2-amino purine 25 sensitivity. To ensure that the insertion is in the *dam* gene, the insertion is cloned and the flanking region is sequenced. The marker may be some other nutritional requirements also. Such markers are useful in distinguishing the vaccine strain from wild type strains.

The subject bacteria are then processed to provide one or more non-reverting mutations. The first mutation will alter a *Dam* function, such as expression, preferably, but 25 not necessarily, by mutating the *dam* gene. If a second mutation is desired, a gene, the loss of which is known to result in attenuation, is further mutated. The mutations may be

deletions, insertions, or inversions, or combinations thereof. Various techniques can be employed for introducing deletions or insertion inversions, so as to achieve a bacteria having the desired "non-leaky" non-reverting mutation resulting in an altered expression of *dam*. The presence of two completely independent mutations, each of which has an 5 extremely low probability of reversion, provides almost absolute assurance that the vaccine strain cannot become virulent.

There are a number of well known techniques which can be employed for disabling or mutating genes, such as the employment of PCR techniques, translocatable elements, mutagenic agents, transducing phages, and DNA-mediated transformation, and/or 10 conjugation. Other methods also known to one with ordinary skill in the art such as recombinant DNA technology may also be employed to successively introduce one or more mutated genes into a single host strain to be used as the vaccine.

After manipulating the bacteria so as to introduce one or more non-reverting mutations into some members of the population, the bacteria are grown under conditions 15 facilitating isolation of the desired mutants, either under conditions under which such mutants have a selective advantage over parental bacteria or under conditions allowing their easy recognition from unaltered bacteria or mutants of other types. The isolated autotrophic mutants are then cloned, screened for virulence, their inability to revert, and their ability to protect the host from a virulent pathogenic strain.

20 The vaccines can be used with a wide variety of domestic animals, as well as humans. Included among domestic animals which are treated by vaccines today or could be treated, if susceptible to bacterial diseases, are chickens, cows, pigs, horses, goats, and sheep, to name the more important domestic animals.

In accordance with the subject invention, the vaccines are produced by introducing 25 a non-reverting mutation in at least one gene, where each mutation is of a sufficient number of bases in tandem to insure a substantially zero probability of reversion. Preferably, the

mutation(s) give rise to non-expression of each mutated gene, in the sense of its total inability to determine production of an active protein, although, as described herein, *Dam* overproducers may also be made. In addition, the gene chosen will be involved in the expression of a DNA adenine methylase and preferably the gene will be *dam*.

5        The resulting strain will be an avirulent live vaccine having the desired immunogenicity, in that the mutation does not affect the production of the antigens which trigger the natural immune response of the host. Typically, when a wild type pathogen reaches a specific tissue within the host a specific virulence factor or set of virulence factors are expressed as a result of the specific environment to which the pathogen is  
10      exposed. It is believed that *Dam*<sup>-</sup> mutants constitutively express many virulence factors all at the same time and not within specific tissues. Since the physiological effect of many virulence factors is tissue specific, the virulence factors that are constitutively expressed in the wrong tissues do not initiate the physiological changes inherent in the disease process. These virulence factors do, however, elicit an immune response from the host. The  
15      immune system thus encounters these factors in an environment where the factors are not able to initiate the necessary physiological changes in the host to cause disease and the host is able to mount an immune response.

      In another embodiment of the present invention, the vaccines are produced by introducing non-reverting mutations in at least two genes, where each mutation is large  
20      enough to insure a substantially zero probability of reversion and assurance of the non-expression of each mutated gene. The first gene chosen will be either directly or indirectly involved in the expression of a DNA adenine methylase. The second gene or genes chosen will also result in attenuation regardless of the attenuating effect of the first gene mutation; however, the second mutation can not affect the protective effects of the first mutation.  
25      The mutations in the first and second gene may be accomplished as discussed previously.

Accordingly, the invention provides a vaccine for provoking (eliciting) an immunological response in a host to be vaccinated comprising: a bacteria having a first mutation in a first gene that alters the expression of a DNA adenine methylase; and a second mutation in said bacteria which renders said microorganism attenuated 5 independently of said first mutation.

In another embodiment, the invention provides live vaccines which may be used as vectors or carriers for an antigen. The antigen may be any antigen, including an antigen of a bacteria genus or species other than the bacteria used in the non-virulent pathogenic vaccine. The antigen may be added as an admixture, attached or associated with the 10 bacteria, or one or more structural genes coding for the desired antigen(s) may be introduced into the non-virulent pathogenic vaccine as an expression cassette.

Accordingly, any of the mutant bacteria described for use in the vaccines described herein may further comprise an expression cassette having one or more structural genes coding for a desired antigen. The expression cassette comprises the structural gene or genes of 15 interest under the regulatory control of the transcriptional and translational initiation and termination regions which naturally border the structural gene of interest or which are heterologous with respect to the structural gene. Where bacterial or bacteriophage structural genes are involved, the natural or wild-type regulatory regions will usually, but not always, suffice. It may be necessary to join regulatory regions recognized by the non- 20 virulent pathogen to structural genes for antigens isolated from eukaryotes and occasionally prokaryotes. Antigens include, but are not limited to, Fragment C of tetanus toxin, the B subunit of cholera toxin, the hepatitis B surface antigen, *Vibrio cholerae* LPS, HIV antigens and/or *Shigella sonnei* LPS.

The expression cassette may be a recombinant construct or may be, or form part of, 25 a naturally occurring plasmid. If the expression cassette is a recombinant construct, it may be joined to a replication system for episomal maintenance or it may be introduced into the

non-virulent pathogenic bacteria under conditions for recombination and integration into the non-virulent pathogen's chromosomal DNA. Structural genes for antigens of interest may encode bacterial proteins such as toxin subunits, viral proteins such as capsids, or enzyme pathways such as those involved in synthesis of carbohydrate antigens such as

5 lipopolysaccharide (LPS). For example, among the antigens expressed in other live attenuated *Salmonella* vaccines are Fragment C of tetanus toxin, the B subunit of cholera toxin, the hepatitis B surface antigen, and *Vibrio cholerae* LPS. Additionally, the HIV antigens GP120 and GAG have been expressed in attenuated *Mycobacterium bovis* BCG and *Shigella sonneii* LPS has been expressed in attenuated *Vibrio cholerae*. The construct or

10 vector may be introduced into the host strain through a number of well known methods such as, transduction, conjugation, transformation, electroporation, transfection, etc.

In another embodiment, live vaccines prepared in accordance with the present invention are prepared having non-reverting mutations in genes that are regulated by an DNA adenine methylase(s), preferably by DNA adenine methylase (Dam). These non-reverting mutations may be prepared as described previously.

In another embodiment, a vaccine is provided for, wherein the bacteria have a mutation which results in the overproduction of Dam, preferably by overproducing DNA adenine methylase (Dam). Methods of producing overproducing bacterial genes are described herein and are known in the art and include, but are not limited to, addition of a

20 plasmid (which may or may not integrate) which carries an additional *dam* gene; alteration of a promoter which controls transcription of *dam*; alteration in the *dam* gene which results in lowered responsiveness to feedback inhibition.

The immunogenic compositions described herein may be used with an adjuvant which enhances the immune response against the pathogenic bacteria such as *Salmonella*.

25 Adjuvants are especially suitable for killed vaccines, but need not be limited to this use. Suitable adjuvants are known in the art and include aluminum hydroxide, alum, QS-21

(U.S. Pat. No. 5,057,540), DHEA (U.S. Pat. Nos. 5,407,684 and 5,077,284) and its derivatives and precursors, e.g., DHEA-S, beta-2 microglobulin (WO 91/16924), muramyl dipeptides, muramyl tripeptides (U.S. Pat. No. 5,171,568) and monophosphoryl lipid A (U.S. Pat. No. 4,436,728; WO 92/16231) and its derivatives, e.g., DETOX™, and BCG (U.S. Pat. No. 4,726,947). Other suitable adjuvants include, but are not limited to, aluminum salts, squalene mixtures (SAF-1), muramyl peptide, saponin derivatives, mycobacterium wall preparations, mycolic acid derivatives, nonionic block copolymer surfactants, Quil A, cholera toxin B subunit, polyphosphazene and derivatives, and immunostimulating complexes (ISCOMs) such as those described by Takahashi et al. (1990) *Nature* 344:873-875. For veterinary use and for production of antibodies in animals, mitogenic components of Freund's adjuvant can be used. The choice of an adjuvant will depend in part on the stability of the vaccine in the presence of the adjuvant, the route of administration, and the regulatory acceptability of the adjuvant, particularly when intended for human use. For instance, alum is approved by the United States Food and Drug Administration (FDA) for use as an adjuvant in humans.

In some embodiments, the immunogenic composition may also comprise a carrier molecule (with or without an adjuvant). Carriers are known in the art. Pltokin, *Vaccines* 3<sup>rd</sup> Ed. Philadelphia, WB Saunders Co. (1999). Bacterial carriers (i.e., carriers derived from bacteria) include, but are not limited to, cholera toxin B subunit (CTB); diphtheria toxin mutant (CRM197); diphtheria toxoid; group B streptococcus alpha C protein; meningococcal outer membrane protein (OMPC); tetanus toxoid; outer membrane protein of nontypeable *Haemophilus influenzae* (such as P6); recombinant class 3 porin (rPorBP of group B meningococci; heat-killed *Burcella abortus*; heat-killed *Listeria monocytogeneis*; and *Pseudomonas aeruginosa* recombinant exoprotein A. Another carrier is keyhole limpet hemocyanin (KLH).

The vaccines of the present invention are suitable for systemic administration to individuals in unit dosage forms, sterile parenteral solutions or suspensions, sterile non-parenteral solutions or oral solutions or suspensions, oil in water or water in oil emulsions and the like. Formulations or parenteral and nonparental drug delivery are known in the art and are set forth in Remington's Pharmaceutical Sciences, 19th Edition, Mack Publishing (1995). The vaccines may be administered parenterally, by injection for example, either subcutaneously, intramuscularly, intraperitoneally or intradermally. Administration can also be **oral**, intranasal, intrapulmonary (i.e., by aerosol), and intravenous. Additional formulations which are suitable for other modes of administration include suppositories and, in some cases, oral formulations. The route of administration will depend upon the condition of the individual and the desired clinical effect. For administration to farm animals, such as chickens, preferred administration is oral formulations. The formulations for the live vaccines may be varied widely, desirably the formulation providing an enhanced immunogenic response.

The subject vaccines and antimicrobial drugs may be used in a wide variety of vertebrates. The subject vaccines and antimicrobial drugs will find particular use with mammals, such as man, and domestic animals. Domestic animals include bovine, ovine, porcine, equine, caprine, domestic fowl, Leporidate e.g., rabbits, or other animals which may be held in captivity or may be a vector for a disease affecting a domestic vertebrate.

Suitable individuals for administration include those who are, or suspected of being, at risk or exposure to bacteria, such as *Salmonella* (*S. spp.*), as well as those who have been exposed and/or infected. The manner of application of the vaccine or antimicrobial drug may be varied widely, any of the conventional methods for administering being applicable. These include oral application, on a solid physiologically acceptable base or in a physiologically acceptable dispersion, parenterally, by injection, or the like. The dosage of the vaccine or antimicrobial drug will depend *inter alia* on route of administration and will

vary according to the species to be protected. One or more additional administrations may be provided as booster doses, usually at convenient intervals, such as two to three weeks. Since DNA adenine methylases are not present in vertebrates, it is likely that inhibitors of DNA adenine methylases when administered to a vertebrate will display zero or low 5 toxicity. Furthermore, since DNA adenine methylases are enzymes, they will be present in low concentrations within the cell; thus, requiring the administration of lower levels of inhibitors and increasing the likelihood that all the DNA adenine methylases will be inhibited.

10 ***Kits and strains***

The invention also provides attenuated strains as described herein. Preferred strains are *Salmonella* strains which contain one or more mutations which alter Dam activity. Similar strains are described herein. Accordingly, in one embodiment, the invention provides attenuated strains of pathogenic bacteria, said bacteria containing a mutation 15 which alters Dam activity such that the bacteria are attenuated. The mutation can be any of those described herein. Preferably, the strain is a *Salmonella* strain.

The present invention also encompasses kits containing any one or more of the strains and/or vaccine formulations described herein in suitable packaging. The kit may optionally provide instructions, such as for administration. In some embodiments, the 20 instructions are for administration to a non-human, such as chicken or other farm animal. In other embodiments, the instruction are for administration to a human.

***Methods of the invention***

The invention also provides methods using the immunogenic compositions 25 described herein, screening methods to identify potentially useful agents which alter Dam activity, as well as methods of preparing the immunogenic compositions described herein.

With respect to any methods involving administration of any of the compositions described herein, it is understood that any one or more of the compositions can be administered, i.e., the compositions can be administered alone or in combination with each other. Further, the compositions can be used alone or in conjunction with other modalities (i.e., clinical intervention), for the purpose of prevention and/or treatment.

*Use of immunogenic compositions for eliciting an immune response, prevention of and treating disease*

In some embodiments, the invention provides methods using the immunogenic compositions described herein to elicit an immune response in an individual. Generally, 10 these methods comprise administering any one or more of the immunogenic compositions described herein to an individual in an amount sufficient to elicit an immune response. The immune response may be against the particular species and/or strain of bacteria in the composition, or, in other embodiments, may be against a second species and/or strain.

The immune response may be a B cell and/or T cell response. Preferably, the 15 response is antigen-specific, i.e., the response is against the bacteria used in the immunogenic composition (i.e., a response against an antigen associated with the bacteria used is detected). Preferably, the immune response persists in the absence of the vaccine components. Accordingly, in some embodiments, the immune response persists for about any of the following after administration of an immunogenic composition described herein 20 (if given as multiple administrations, preferably after the most recent administration): four weeks, six weeks, eight weeks, three months, four months, six months, one year.

In order to determine the effect of administration of an immunogenic composition described herein, the individual may be monitored for either an antibody (humoral) or 25 cellular immune response against the bacteria, or a combination thereof, using standard techniques in the art. Alternatively, if an immunogenic composition is already proven to elicit such a response, such monitoring may not be necessary.

For the purpose of raising an immune response, the immunogenic compositions described herein may be administered in an unmodified form. It may sometimes be preferable to modify the bacteria to improve immunogenicity. As used herein, and as well known in the art, "immunogenicity" refers to a capability to elicit a specific antibody (B cell) or cellular (T cell) immune response, or both. Methods of improving immunogenicity include, *inter alia*, crosslinking with agents such as glutaraldehyde or bifunctional couplers, or attachment to a polyvalent platform molecule. Immunogenicity may also be improved by coupling to a protein carrier, particularly one that comprises T and/or B cell epitopes.

Suitable individuals for receiving the compositions have been described above and likewise apply to these methods. Generally, such individuals are susceptible to exposure to, have been exposed to, and/or display a symptom and/or disease state associated with infection. The individual may or may not have been exposed to *Salmonella* at the time of administration, and accordingly may or may not have been infected by *Salmonella* at the time of administration. Preferably, the individual has not been exposed to *Salmonella*.

In some embodiments, the invention provides methods of eliciting an immune response to a second species, strain, serotype, and/or group of *Salmonella*, in an individual, comprising administering to the individual any of the immunogenic compositions described herein in an amount sufficient to elicit an immune response to the second species, strain, serotype, and/or group of *Salmonella*. The individual may or may not have been previously exposed to the second species, strain, serotype, and/or group of *Salmonella*. In some embodiments, the second *Salmonella* against which an immune response is elicited is from a second group, such as Group A, B, or D (as compared to the first serotype administered). In other embodiments, the second *Salmonella* against which an immune response is elicited is from a second serotype (as compared to the first serotype administered).

A first and second species may be any species of *Salmonella*, some of which have been described above. In some embodiments, the first species is *S. typhimurium* and the

second species is *S. enteritidis*. In some embodiments, the first species is *S. typhimurium* and the second species is *S. dublin*. In other embodiments, the first species is *S. enteritidis* and the second species is *S. typhimurium*. In yet other embodiments, the first species is *S. enteritidis* and the second species is *S. dublin*. Similarly, the first group may be any of the 5 known groups of *Salmonella*, such as Group A, B, or D. The second group may be any known, such as Group A, B, or D (provided that the second group is different from the first group). In other embodiments, the first serotype is different than the second serotype.

Serotypes of *Salmonella* are known in the art.

It is understood that an immune response may be elicited against one or more 10 additional antigens (i.e., one or more additional *Salmonella* strains, groups, serotypes, and/or species). Thus, the invention encompasses methods by which an immune response is elicited against a third, fourth, fifth, etc. *Salmonella* strain, group, serotype, and/or species.

The invention also encompasses methods of eliciting an immune response to a 15 second species, strain, serotype and/or group of a pathogenic bacteria in an individual comprising administering to the individual an immunogenic composition comprising an attenuated bacteria which is a *Dam* derivative amount sufficient to elicit an immune response to a second species, strain, serotype and/or group of the pathogenic bacteria.

The invention also provides methods of treating a bacterial, preferentially, such as 20 *Salmonella*, infection in an individual. In some embodiments, the invention provides methods of suppressing a disease symptom associated with infection of a virulent bacteria, such as *Salmonella*. The methods comprise administering any one or more of the compositions described herein in an amount sufficient to suppress a disease symptom associated with infection. Preferentially, the infection is due to *Salmonella*. In other 25 embodiments, the infection is due to *Escherichia*, preferably *E. coli*. In other embodiments, these methods comprise administering any one or more of the compositions described

herein in an amount to reduce the amount of pathogenic bacteria, such as *Salmonella*, in an individual (as compared to non-administration).

The vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective. The quantity to be administered 5 depends on the individual to be treated, the capacity of the individual's immune system to synthesize antibodies, the route of administration, and the degree of protection desired. Precise amounts of active ingredient required to be administered may depend on the judgment of the practitioner in charge of treatment and may be peculiar to the individual.

In one embodiment, the invention provides methods of treating an individual 10 infected with a pathogenic bacteria, comprising administering to the individual a composition comprising an agent which alters Dam activity. In other embodiments, the invention provides methods of treating a host infected with a pathogenic microorganism (bacteria) comprising (a) administering a compound to the host, wherein said compound alters the expression of or activity of one or more DNA adenine methylases. The 15 compound(s) may (a) bind to one or more DNA adenine methylases thereby altering the activity of said DNA adenine methylases; (b) bind to one or more genes that express a DNA adenine methylase, thereby altering the expression of said DNA adenine methylase(s). The expression of said DNA adenine methylase(s) is/are overactive. Alternatively the expression of said DNA adenine methylase(s) is/are repressed. In some 20 embodiments, the compound is an antisense oligonucleotide having a sequence complementary to one or more DNA adenine methylase gene sequences.

The invention also provides methods of treating a host infected with a pathogenic microorganism (bacteria) comprising administering a compound to the host, wherein said compound binds one or more virulence factors that are regulated by DNA adenine 25 methylases.

In some embodiments, the invention provides methods of preventing bacterial infection, such as *Salmonella* infection. In these embodiments, an immune response elicited by the immunogenic composition(s) is protective in the sense that a recipient of the immunogenic composition displays one or more lessened symptoms of infection when compared to an individual not receiving the composition. In other embodiments, a protection is conferred by reducing amount of bacteria, such as *Salmonella*, in the individual receiving the composition as compared to not receiving the composition.

In some embodiments, the invention provides methods of suppressing a symptom associated with bacterial infection in an individual (or, alternatively, methods of treating a bacteria infection) comprising administering to the individual a composition comprising an agent which alters Dam activity. A bacteria may be any of those described herein, particularly *Salmonella*.

In another embodiment, an antimicrobial drug in accordance with the present invention is prepared which inhibits a DNA adenine methylase(s), preferably DNA adenine methylase (Dam). While the following discussion focuses specifically on the *dam* gene and its product, Dam, it is to be understood that this specificity is only for the purpose of simplicity and clarity. It is contemplated that the methods and compositions discussed below are applicable towards (i) any gene that expresses a DNA adenine methylase, (ii) any gene or gene product that regulates a DNA adenine methylase gene, (iii) any gene that is regulated by a DNA adenine methylase, and/or (iv) DNA methylases. Consequently, while a specific gene and gene product, that is *dam* and Dam, are discussed below, it is contemplated that other DNA adenine methylase genes and DNA adenine methylases are equivalents of *dam* and Dam, respectively, and are thus interchangeable with respect to the discussion which follow.

Inhibition of Dam could be carried out by a number of approaches including use of antisense oligonucleotides to inhibit *dam* gene translation, direct inhibitors of Dam

enzymatic activity, reduction of Dam levels by isolation of inhibitory compounds for Dam activators and/or activating compounds for Dam repressors, and targeting of virulence factors that are regulated by Dam. The antisense approach has been used previously to inhibit the cytosine methyltransferase (MeTase) from mammalian cells (MacLeod, A. R. 5 and Szyf, M., *J. Biol. Chem.*, 7:8037-8043 (1995)). Transfection of an antisense nucleic acid into adrenocortical cells resulted in DNA demethylation and reduced tumorigenicity associated with MeTase activity.

In another embodiment, the anti-microbial drug activates Dam. Such a compound could effect such activation by, for example, stimulating the *dam* promoter, inactivating 10 repressors, and/or extend half-life of Dam.

#### Screening assays

The present invention also encompasses methods of identifying agents that may have anti-bacterial activity (and thus may control virulence) based on their ability to alter 15 Dam activity. These methods may be practiced in a variety of embodiments. We have observed that loss or even increase of Dam function results in significantly lower infectivity of *Salmonella* in an art-accepted mouse model. This suggests that modulation of Dam function may result in control of the pathogenesis of various bacteria, including, but not limited to, *Salmonella*, while not affecting host cells. This is especially true since 20 humans do not have a homolog to *dam* genes. Further, we have found that *dam* is an essential gene in *Vibrio cholerae* and *Yersinia pseudotuberculosis* (Example 7), which indicates that Dam is an excellent drug target in these pathogenic organisms. Thus, an agent identified by the methods of the present invention may be useful in the treatment of bacterial infection, especially *Escherichia*, *Salmonella*, *Vibrio*, and/or *Yersinia* infection.

25 The methods described herein are in vitro and cell-based screening assays. In the in vitro embodiments, an agent is tested for its ability to modulate function of Dam. In the

cell-based embodiments, living cells having Dam function are used for testing agents. For purposes of this invention, an agent may be identified on the basis of any alteration of Dam function, although characteristics associated with total loss of Dam function may be preferable.

5        In all of these methods, alteration of Dam function may occur at any level that affects Dam function, whether positively or negatively. An agent may alter Dam function by reducing or preventing transcription of Dam. An example of such an agent is one that binds to the upstream controlling region, including a polynucleotide sequence or polypeptide. An agent may alter Dam function by increasing transcription of Dam RNA.

10      An agent may alter Dam function by reducing or preventing translation of Dam RNA. An example of such an agent is one that binds to the RNA, such as an anti-sense polynucleotide, or an agent which selectively degrades the RNA. Anti-sense approaches to inhibiting Dam have been described above. An agent may alter Dam function by increasing translation of Dam RNA. An agent may compromise Dam function by binding

15      to Dam. An example of such an agent is a polypeptide or a chelator. An agent may compromise Dam function by affecting gene expression of a gene that is regulated by Dam. An example of such an agent is one that alters expression of a Dam-regulated gene on any of the levels discussed above.

20      The screening methods described as applicable to any pathogenic bacteria having a Dam gene.

In vitro screening methods

25      In in vitro screening assays of this invention, an agent is screened in an in vitro system, which may be any of the following: (1) an assay that determines whether an agent is inhibiting or increasing transcription of *dam*; (2) an assay for an agent which interferes with translation of Dam RNA or a polynucleotide encoding Dam, or alternatively, an agent which specifically increases translation of *dam*; (3) an assay for an agent that binds to Dam.

For an assay that determines whether an agent inhibits or increases transcription of *dam*, an in vitro transcription or transcription/translation system may be used. These systems are available commercially, and generally contain a coding sequence as a positive, preferably internal, control. A polynucleotide encoding Dam is introduced and

5 transcription is allowed to occur. Comparison of transcription products between an in vitro expression system that does not contain any agent (negative control) with an in vitro expression system that does contain agent indicates whether an agent is affecting *dam* transcription. Comparison of transcription products between control and Dam indicates whether the agent, if acting on this level, is selectively affecting transcription of *dam* (as

10 opposed to affecting transcription in a general, non-selective or specific fashion).

For an assay that determines whether an agent inhibits or increases translation of *dam* RNA or a polynucleotide encoding Dam, an in vitro transcription/translation assay as described above may be used, except the translation products are compared. Comparison of translation products between an in vitro expression system that does not contain any

15 agent (negative control) with an in vitro expression system that does contain agent indicates whether an agent is affecting *dam* translation. Comparison of translation products between control and *dam* indicates whether the agent, if acting on this level, is selectively affecting translation of *dam* (as opposed to affecting translation in a general, non-selective or specific fashion).

20 For an assay for an agent that binds to Dam, Dam is first recombinantly expressed in a prokaryotic or eukaryotic expression system as a native or as a fusion protein in which Dam is conjugated with a well-characterized epitope or protein. Recombinant Dam is then purified by, for instance, immunoprecipitation using anti-Dam antibodies or anti-epitope antibodies or by binding to immobilized ligand of the conjugate. An affinity column made

25 of Dam or Dam fusion protein is then used to screen a mixture of compounds which have been appropriately labeled. Suitable labels include, but are not limited to, fluorochromes,

radioisotopes, enzymes and chemiluminescent compounds. The unbound and bound compounds can be separated by washes using various conditions (e.g. high salt, detergent) that are routinely employed by those skilled in the art. Non-specific binding to the affinity column can be minimized by pre-clearing the compound mixture using an affinity column containing merely the conjugate or the epitope. A similar method can be used for screening for agents that competes for binding to Dam. In addition to affinity chromatography, there are other techniques such as measuring the change of melting temperature or the fluorescence anisotropy of a protein which will change upon binding another molecule. For example, a BIACore assay using a sensor chip (supplied by 5 Pharmacia Biosensor, Stitt et al. (1995) *Cell* 80: 661-670) that is covalently coupled to native Dam or Dam-fusion proteins, may be performed to determine the Dam binding 10 activity of different agents.

With respect to binding Dam, it is understood that suitable fragments of Dam could also be used. For example, if it is known that a particular region of Dam is important for 15 binding to DNA, then this fragment containing or even consisting of this region could be used.

In another embodiment, an in vitro screening assay detects agents that compete with another substance (most likely a polynucleotide) that binds Dam. For instance, it is known that Dam binds a certain DNA motif, namely GATC, which is a Dam target site. An assay 20 could be conducted such that an agent is tested for its ability to compete with binding to this motif(s). Competitive binding assays are known in the art and need not be described in detail herein. Briefly, such an assay entails measuring the amount of Dam complex formed in the presence of increasing amounts of the putative competitor. For these assays, one of the reactants is labeled using, for example, <sup>32</sup>P. One such assay, also encompassed by this 25 invention, is described in more detail below.

Isolation of inhibitors or activators of Dam could be carried out, for example, by screening chemical (Neustadt, *et al.*, *Bioorg. Med. Chem. Lett.*, **8**:2395-2398 (1998)) or peptide libraries (Lam, K.S., *Anticancer Drug. Res.*, **12**:145-167 (1997)) using a rapid, high throughput assay for Dam. Such inhibitor libraries have already been shown to be effective

5 in blocking the activity of several enzymes (Carroll, C.D., *Bioorg. Med. Chem. Lett.*, **8**:3203-3206 (1998)). This Dam assay consists of a double stranded oligonucleotide containing Dam target sites (GATC sequences) with a tethering group on one end (e.g. biotin) and a signal at the other end. This signal could be a radioactive compound such as phosphorous-32, an fluorescent molecule such as fluorescein, or an antigen. The

10 nonmethylated oligonucleotide containing Dam target sites is tethered to a solid surface such as a 96-well microtiter plates containing avidin. Dam enzyme (predetermined to contain just sufficient activity to methylate all of the GATC sites of the target oligonucleotide) is preincubated with inhibitor libraries and then added to each well in the presence of S-adenosylmethionine (SAM). Following an incubation period, sample wells

15 are rinsed in buffer and restriction enzyme *Mbo*I is added to digest all nonmethylated GATC sites within the oligonucleotide, thus releasing the signal end of the molecule. Plate wells are then counted (radioactive signal), scanned for fluorescence (fluorescent signal), or incubated with secondary antibody conjugated to an enzyme such as horse radish peroxidase, followed by a non-radioactive substrate of the enzyme. Inhibition of Dam

20 would be detected as a reduction in signal within a sample well due to release of nonmethylated GATC sites. This assay could be used to rapidly screen chemical and peptide libraries for inhibitory activity. The feasibility of such studies has been shown by the isolation of sinefungin, an inhibitor of MeTase activity. Sinefungin is an analog of S-adenosyl-L-methionine (SAM), and acts as a competitive inhibitor of DNA methylation.

25 However, because sinefungin would block all DNA methylases including the mammalian

cytosine methylase that require SAM as methyl donor, this drug would not be useful as a chemotherapeutic agent against bacteria.

To isolate activators of Dam, Dam (predetermined to contain sufficient activity to methylate a low percentage of target sites, such as GATC sites, of the target 5 oligonucleotide, for example, 20%) is preincubated with one or more agents (including activator libraries) and then added to each well in the presence of SAM. Activation of Dam would be detected as an increase in signal within the sample well due to methylation of the target sites (such as GATC) and thus prevention of *MboI* restriction reaction.

Accordingly, in some embodiments, the invention provides methods of identifying 10 an agent which alters or modulates (i.e., an agent which alters Dam function, preferably inhibits Dam function), comprising the steps of (a) tethering a nonmethylated oligonucleotide containing a DNA adenine methylase target site to a solid surface wherein said nonmethylated oligonucleotide has a tethering group on a first end and a signal on a second end; (b) incubating a DNA adenine methylase having sufficient activity to 15 methylate said target sites, preferably all of said target sites, on said nonmethylated oligonucleotide with an agent; inhibitor libraries; (c) adding said incubated DNA adenine methylase to said tethered nonmethylated oligonucleotide in the presence of S-adenosylmethionine; (d) digesting all nonmethylated target sites, thereby releasing said tethered nonmethylated oligonucleotides; and (e) detecting inhibition of DNA adenine 20 methylase as an increase in said signal due to digestion of said nonmethylated target sites. Preferably, the target site is a GATC sequence. The tethering group may be any suitable moiety known in the art, such as biotin. The signal may be due to fluorescence, radioactivity, or an antigen. In some embodiments, the solid surface is a microtiter plate containing avidin. A restriction enzyme, such as *MboI*, may be used to digest said 25 nonmethylated target sites. If an inhibitor library is used as a source of agents to be tested,

the library may comprise biomolecules, such as peptides, or may comprise organic compounds or inorganic compounds.

It is also understood that the in vitro screening methods of this invention include structural, or rational, drug design, in which the amino acid sequence, three-dimensional atomic structure or other property (or properties) of Dam provides a basis for designing an agent which is expected to bind to Dam. Generally, the design and/or choice of agents in this context is governed by several parameters, such as the perceived function of the Dam target (here, binding DNA is one such function), its three-dimensional structure (if known or surmised), and other aspects of rational drug design. Techniques of combinatorial chemistry can also be used to generate numerous permutations of candidate agents. For purposes of this invention, an agent designed and/or obtained by rational drug design may also be tested in the cell-based assays described below.

#### Cell-based screening methods

In cell-based screening assays, a living cell, preferably a bacterium containing a functioning *dam* gene, or a living cell, preferably a bacterium containing a polynucleotide construct comprising a Dam encoding sequence, are exposed to an agent. In contrast, conventional in vitro drug screening assays (as described above) have typically measured the effect of a test agent on an isolated component, such as an enzyme or other functional protein.

The cell-based screening assays described herein have several advantages over conventional drug screening assays: 1) if an agent must enter a cell to achieve a desired therapeutic effect, a cell-based assay can give an indication as to whether the agent can enter a cell; 2) a cell-based screening assay can identify agents that, in the state in which they are added to the assay system are ineffective to alter Dam function, but that are modified by cellular components once inside a cell in such a way that they become effective agents; 3) most importantly, a cell-based assay system allows identification of

agents affecting any component of a pathway that ultimately results in characteristics that are associated with alteration of Dam function.

In one embodiment, an agent is identified by its ability to elicit a characteristic associated with an alteration of Dam function in a suitable host cell. A suitable host cell in 5 this context is any host cell in which a Dam function may be observed. Preferably, the host cell is a bacterial cell. Suitable host cells include, but are not limited to, *Salmonella*, *Escherichia*, *Vibrio*, *Yersinia*, and any other bacteria genus and species that contains a *Dam* gene. One example of an assay uses the pili operon system in *E. coli*, in which level of expression of a reporter is determined. Any bacterial operon system which is responsive to 10 methylation would be suitable for bacterial-based assays, using any of a number of reporter systems known in the art. Levels of transcription and/or translation from such systems in the presence of agent(s) would indicate whether an agent was affecting Dam activity.

In one embodiment, the invention provides methods for identifying an agent that may control virulence comprising the following steps: (a) contacting at least one agent to 15 be tested with a suitable host cell that has Dam function; and (b) analyzing at least one characteristic which is associated with alteration of Dam function (which can be increase, decrease, or loss of Dam function) in said host cell, wherein an agent is identified by its ability to elicit at least one such characteristic. For these methods, the host cell may be any cell in which Dam function has been demonstrated.

20 For genes that are de-repressed upon loss of Dam function, loss of Dam function may be measured using a reporter system, in which a reporter gene sequence is operatively linked to the Dam-repressed gene of interest. Such repressed genes are described herein, including the examples. As used herein, the term "reporter gene" means a gene that encodes a gene product that can be identified (*i.e.*, a reporter protein). Reporter genes 25 include, but are not limited to, alkaline phosphatase, chloramphenicol acetyl transferase,  $\beta$ -galactosidase, luciferase and green fluorescence protein. Identification methods for the

products of reporter genes include, but are not limited to, enzymatic assays and fluorometric assays. Reporter genes and assays to detect their products are well known in the art and are described, for example in Current Protocols in Molecular Biology, eds. Ausubel et al., Greene Publishing and Wiley-Interscience: New York (1987) and periodic updates, as well as Short Protocols in Molecular Biology (Wiley and Sons, 1999). Reporter genes, reporter gene assays and reagent kits are also readily available from commercial sources (Strategene, Invitrogen and etc.)

5 In another embodiment, these methods comprise the following steps:

(a) introducing a polynucleotide encoding Dam (or a functional fragment thereof) into a  
10 suitable host cell that otherwise lacks Dam function, wherein Dam function is restored in  
said host cell; (b) contacting said cell of step (a) with at least one agent to be tested;  
(c) analyzing at least one characteristic which is associated with loss of Dam function,  
wherein an agent is identified by its ability to elicit at least one said characteristic.

15 The host cell used for these methods initially lacks Dam function (i.e., lacks Dam function before introduction of polynucleotide encoding Dam). Lacking Dam function may be partial to total. Devising host cells that lack Dam function may be achieved in a variety of ways, including, but not limited to, genetic manipulation such as deletion mutagenesis, recombinant substitution of a functional portion of the gene, frameshift mutations, conventional or classical genetic techniques pertaining to mutant isolation, or alterations of  
20 the regulatory domains. For cells in which loss of Dam (or its homolog) function is lethal, a plasmid containing a wild type copy of the Dam is in the cell during the disruption, or mutagenesis, process. If the cells cannot survive without the plasmid containing the wild-type gene, then it is assumed that the loss of Dam function is lethal. Example 7 describes an assay for determining whether a *Dam* gene is essential.

25 Introduction of polynucleotides encoding Dam or a functional fragment thereof depend on the particular host cell used and may be by any of the many methods known in

the art, such as spheroplasting, electroporation,  $\text{CaCl}_2$  precipitation, lithium acetate treatment, and lipofectamine treatment.

Polynucleotides introduced into a suitable host cell(s) are polynucleotide constructs comprising a polynucleotide encoding Dam or a functional fragment thereof. These constructs contain elements (i.e., functional sequences) which, upon introduction of the construct, allow expression (i.e., transcription, translation, and post-translational modifications, if any) of Dam amino acid sequence in the host cell. The composition of these elements, such as appropriate selectable markers, will depend upon the host cell being used.

Restoring Dam (or its homolog) function in the host cell(s) may be determined by analyzing the host cell(s) for detectable parameters associated with Dam function (i.e., wild type). These parameters depend upon the particular host cell used. For *Salmonella*, Dam function is associated with any of the following: (a) repression of Dam-regulated genes; (b) virulence; (c) regulation of paf pili expression; (d) lack of sensitivity of certain amino acids. Genes known to be repressed in the presence of Dam in *Salmonella* have been described above. Given methods well known in the art for making reporter constructs (see above), any of these genes could be altered to accommodate a reporter system. Examples of suitable reporter systems have been discussed above.

In some embodiments, a polynucleotide encoding Dam is operatively linked to an inducible promoter. Use of an inducible promoter provides a means to determine whether the agent is acting via a Dam pathway. If an agent causes a characteristic indicative of loss of Dam function to appear in a cell in which the inducible promoter is activated, an observation that the agent fails to elicit the same result in a cell in which the inducible promoter is not activated indicates that the agent is affecting at least one step or aspect of Dam function. Conversely, if the characteristic indicating loss of Dam function is also

observed in a cell in which the inducible promoter is not activated, then it can be assumed that the agent is not necessarily acting solely via the Dam functional pathway.

Cell-based screening assays of the present invention can be designed, *e.g.*, by constructing cell lines in which the expression of a reporter protein, *i.e.*, an easily assayable 5 protein, such as  $\beta$ -galactosidase, chloramphenicol acetyltransferase (CAT), green fluorescent protein (GFP) or luciferase, is dependent on Dam function. For example, a gene under Dam control may have reporter sequences inserted within the coding region as described in Example 1. The cell is exposed to a test agent, and, after a time sufficient to effect  $\beta$ -galactosidase expression and sufficient to allow for depletion of previously 10 expressed  $\beta$ -galactosidase, the cells are assayed for the production of  $\beta$ -galactosidase under standard assaying conditions.

Assay methods generally require comparison to a control sample to which no agent is added. Additionally, it may be desirable to use a cell partially or completely lacking Dam function as a control. For instance, if an agent were acting along a Dam pathway, one 15 might expect to see the same phenotype as *dam*<sup>-</sup> cells treated with agents. If an agent were not acting along a Dam pathway, one may expect to see other characteristics that occur in the *dam*<sup>-</sup> cells when treated with the agent.

The screening methods described above represent primary screens, designed to detect any agent that may exhibit anti-bacterial activity. The skilled artisan will recognize 20 that secondary tests will likely be necessary in order to evaluate an agent further. For example, a secondary screen may comprise testing the agent(s) in bacteria of interest if the initial screen has been performed in a host cell other than those bacteria. A further screen is to perform an infectivity assay using the cells that have been treated with the agent(s). An infectivity assay using mice is described in Example 1, and other animal models (such 25 as rat) are known in the art. In addition, a cytotoxicity assay would be performed as a further corroboration that an agent which tested positive in a primary screen would be

suitable for use in living organisms. Any assay for cytotoxicity would be suitable for this purpose, including, for example the MTT assay (Promega).

Preparation of vaccines and attenuated bacteria

The invention also provides methods of preparing, or making, the vaccines 5 described herein as well as methods of making the mutant strains (i.e., Dam derivatives) described herein. Preparation of vaccines has been discussed above and as such, these methods are included in the invention. It is understood that any of the mutations described herein (including those which increase, decrease, or eliminate Dam activity, including Dam expression) may be used in the methods of preparation of the invention, and are generally 10 not repeated in this section.

In one embodiment, the invention provides methods for preparing an immunogenic composition comprising attenuated bacteria with altered Dam function, comprising combining any of the mutants and/or mutant strains described herein (i.e., Dam derivatives) with a pharmaceutically acceptable excipient. Preferred embodiments include *Salmonella* 15 strains such as those described herein. Particularly preferred are *Salmonella* strains which have mutations which have eliminated Dam activity, such as those deletion mutants described herein.

In one embodiment, the invention provides methods for preparing an attenuated pathogenic bacteria, preferably *Salmonella*, capable of eliciting an immunological response 20 by a individual susceptible to disease caused by the corresponding or similar pathogenic bacteria comprising constructing at least one mutation in said pathogenic bacteria wherein a first mutation results in alteration of Dam function, preferably the altered expression of a Dam. Preferably, the first mutation is introduced into a first gene that expresses Dam. In some embodiments, said first mutation is introduced into a first gene, the expression of 25 which represses or over activates expression of a gene that expresses a DNA adenine methylase enzyme. In some embodiments, said first mutation is introduced into a first gene

the expression of which is regulated by a DNA adenine methylase. In other embodiments, a second mutation is created in a gene that is independent of said first mutation, said second mutation causing attenuation of the bacteria.

In another embodiment, the invention provides methods for preparing an attenuated 5 bacteria capable of eliciting an immunological response by a host susceptible to disease caused by the corresponding virulent bacteria comprising (a) constructing at least one mutation in the *dam* gene of a virulent strain of the pathogenic bacteria. In some embodiments, a second mutation is introduced into a second gene which results in attenuation of said bacteria independently of said first mutation.

10 In another embodiment, the invention provides methods for preparing an attenuated bacteria capable of eliciting an immunological response by a host susceptible to disease caused by the corresponding or similar pathogenic bacteria comprising (a) constructing a first non-reverting mutation in said pathogenic bacteria wherein said first non-reverting mutation alters the expression of or the activity of one or more DNA adenine methylases, 15 and (b) constructing a second non-reverting mutation in said pathogenic bacteria wherein said second non-reverting mutation is independent of said first non-reverting mutation and is attenuating. In some embodiments, the first non-reverting mutation is constructed in a gene whose product activates one or more of said DNA adenine methylases. In some embodiments, the gene product activates DNA adenine methylase. In some embodiments, 20 the first non-reverting mutation is constructed in a gene whose product represses the expression of said DNA adenine methylases. In some embodiments, said gene product represses DNA adenine methylase. In other embodiments, the first non-reverting mutation is constructed in a gene whose product inactivates or decreases the activity of one or more of said DNA adenine methylases by binding directly to one or more of said DNA adenine 25 methylases. In some embodiments, one of said DNA adenine methylases is DNA adenine methylase. In some embodiments, the pathogenic bacteria is a strain of *Salmonella*,

preferably *Salmonella* is *S. typhimurium*, *S. enteritidis*, *S. typhi*, *S. bortis-ovi*, *S. abortus-equi*, *S. dublin*, *S. gallinarum*, *S. pullorum*. In other embodiments, the pathogenic bacteria are any one of the following: *Yersinia*, *Vibrio*, *Shigella*, *Haemophilus*, *Bordetella*, *Neisseria*, *Pasteurella*, *pathogenic Escherichia*, *Treponema*. The host may be a vertebrate, 5 such as a mammal, preferably human or a domestic animal. In some embodiments, the vertebrate is a chicken.

In some embodiments, the preparation methods comprise addition of an antigen. For example, the antigen can be added simply to the bacteria in the vaccine, or, alternatively, expression cassette comprising one or more structural genes coding for a 10 desired antigen may be inserted into the attenuated bacteria.

Antigens include, but are not limited to, Fragment C of tetanus toxin, the B subunit of cholera toxin, the hepatitis B surface antigen, *Vibrio cholerae* LPS, HIV antigens and/or *Shigella sonneii* LPS.

In another embodiment, the invention provides methods for preparing an attenuated 15 microorganism capable of eliciting an immunological response by a host susceptible to disease caused by the corresponding or similar pathogenic microorganism comprising the steps of (a) constructing a first non-reverting mutation in said pathogenic microorganism wherein said first non-reverting mutation alters the expression of or activity of one or more genes that are regulated by DNA methylases; and (b) constructing a second non-reverting 20 mutation in said pathogenic microorganism wherein said second non-reverting mutation is independent of said first non-reverting and is attenuating.

The above disclosure generally describes the present invention. A more complete 25 understanding can be obtained by reference to the following specific examples which are provided herein for purposes of illustration only and are not intended to be limiting.

## EXAMPLES

The following non-limited examples provide vaccines prepared from live, pathogenic bacteria and the target sites for antimicrobial drugs according to the teachings of the present invention, and are offered only by way of illustration and not by way of limitation. All scientific technical terms have the meanings as understood by one with ordinary skill in the art. Recombinant DNA techniques are now sufficiently well known and widespread so as to be considered routine. In very broad and general terms, these techniques entail transferring the genetic material of one organism into a second organism so that the transferred genetic material becomes a part of the genetic material of the organism to which it is transferred. This typically consists of first obtaining a piece of DNA from the first organism either from a plasmid or the chromosomal DNA. The piece of DNA may be of any size and is often obtained through the use of restriction endonuclease enzymes which recognize and cut DNA at specific base pair sites.

Following the isolation of a particular piece of DNA, the DNA may be inserted or cloned into plasmid, phage or cosmid vectors to form recombinant molecules that may be subsequently transferred into a host cell by various means such as transformation, transduction, transfection, and conjugation.

Transformation involves the uptake of naked DNA from the external environment, which can be artificially induced by the presence of various chemical agents such as calcium ions, or by electroporation. Transduction involves the packing of the recombinant DNA within a phage, such as transducing phage or cosmid vectors. Once the recombinant DNA is introduced into the microbial host, it may continue to exist as a separate piece or it may insert or integrate into the host cell's chromosome and be reproduced with the chromosome during cell division. Conjugation involves classical microbial mating techniques.

**Example 1: Dam *Salmonella* derivatives are avirulent****Strain Construction**

All *Salmonella typhimurium* strains used were isogenic with American Tissue Culture Collection (ATCC) strain 14028, a smooth virulent strain of *S. typhimurium* referred to as "wild type". Previously, all reported *dam* mutations from other laboratories used *Salmonella* strain LT2 which is at least 1000-fold less virulent than the wild type when delivered i.p. See the data in Table 1.

All restriction enzymes and pBR322 were, and can be, purchased from commercial sources, such as Stratagene, 11099 North Torrey Pines Rd., La Jolla, California 92037. Electroporation was carried out with a BioRad Gene Pulser apparatus Model No. 1652098. *S. typhimurium* cells were prepared as per the manufacturer's instructions. Aliquots of competent cells were mixed with an aliquot of the desired plasmid and placed on ice for 1 minute. The mixture was transferred into a cuvette-electrode (0.2 cm) and pulsed once at a field strength of 2.5 KV/cm as per the manufacturer's instructions.

**1. Construction of Nonpolar *dam* mutant**

For construction of a nonpolar *dam* mutant, *S. typhimurium* genomic DNA was used as template for the PCR using Pfu polymerase (Stratagene). A 350-bp DNA fragment containing the first 100 codons of *dam* was amplified by PCR using the following oligonucleotide pair: 5'-GATTCTAGAGTAGTCTGCGGAGCTTC- 3' (SEQ ID NO. 1) (containing an *Xba*I site at the 5' end) and 5'-GATTCTCGAGGGTGTGAACTCCTCGCG- 3' (SEQ ID NO. 2) (containing an *Xho*I site at the 5' end). PCR was carried out in a buffer containing 2.0 mM Mg<sup>2+</sup> for 30 cycles of 45 seconds at 92°C, 1 minute at 42°C and 1 minute 30 seconds at 72°C. This procedure was carried out in a DNA Thermal Cycler #N801-0150 (Perkin-Elmer Cetus). The PCR product was then double-digested with *Xba*I and *Xho*I. In a second PCR

amplification, a 300-bp DNA fragment containing the last 79 codons of *dam* was synthesized using the following oligonucleotide pair: 5'-  
GATTCTCGAGTTAGCCTGACGCAACAAG- 3' (SEQ ID NO. 3) (containing an  
5 *Xho*I site at the 5' end) and 5'-GATTGCATGCTCCTCACCCAGGCGAG-3' (SEQ ID  
NO. 4) (containing an *Sph*I site at the 5' end). This PCR product was then double  
digested with *Xho*I and *Sph*I. The suicide vector pCVD442 (Donnenberg, M. S., *et al.*,  
*Infect. Immun.*, 59:4310-4317 (1991)), was double digested with *Xba*I and *Sph*I, band  
purified, and ligated in a single reaction with the two custom-cut PCR products. An in-  
frame deletion of 100 internal amino acids of Dam was created, leaving a unique *Xho*I  
10 site at the deletion join point. *E. coli* DH5alpha lambda *pir* was then transformed  
selecting ampicillin resistance. DNA from the appropriate ampicillin resistant construct  
(confirmed by restriction digest) was then used to transform *S. typhimurium* 14028. The  
integrated pCVD442-containing construct was then segregated on LB 5% sucrose/no salt  
plates. Segregants were confirmed ampicillin sensitive by printing and Dam<sup>+</sup> by  
15 streaking on LB plates containing 2-aminopurine (0.6mg/ml) (Dam mutants are 2-AP  
sensitive). Additionally, PCR was used to confirm the deletion by size in comparison to  
wild-type sequences. Lastly, the deleted region was cloned into pGP704 and sequence  
near and at the deletion join point (including the *Xho*I site) was obtained to confirm that  
the deletion in fact was in-frame.

20 The mutation caused by the *dam102* insertion (*dam102::Mud-Cm* discussed  
above) was moved by P22-mediated transduction into virulent *Salmonella* strain, 14028  
to construct strain 2.

## 2. Mouse virulent assays

25 Virulent properties of all the various *S. typhimurium* strains constructed, as  
described above, were tested by intraperitoneal or oral inoculations of female BALB/c  
mice and the results are presented in Table 1 below.

Female BALB/c mice were purchased from Charles River Breeding Laboratories, Inc., (Wilmington, Mass.) and were 6 to 8 weeks of age at initial challenge. *S. typhimurium* strains were grown overnight at 37°C to stationary phase in Luria Broth (LB). Bacteria were washed once with PBS, then diluted in PBS to the approximate 5 appropriate dilution (samples were plated for colony forming units (CFUs) on LB to give an accurate bacterial count). Mice were challenged with 200 µl of the appropriate bacterial dilutions either intraperitoneally or perorally. For peroral inoculations bacteria were washed and concentrated by centrifugation, the bacteria were then resuspended in 0.2M Na<sub>2</sub>HPO<sub>4</sub> at pH 8.0, to neutralize stomach acid, and administered as a 0.2 ml bolus 10 to animals under ether anesthesia. For all LD<sub>50</sub> determinations, 5 mice each were inoculated per dilution. Control mice received PBS only.

All bacterial strains used in this study were derivatives of *S. typhimurium* 14028 (strain 1). Mutant strains were isogenic to wild type and were obtained or constructed as described (*dam102::Mud-Cm* and *mutS121::Tn10* alleles are in LT2 (strain 7), a highly 15 attenuated (virtually non-pathogenic) strain as shown in Table 2, were obtained from Dr. John Roth (University of Utah) and Dr. Tom Cebula (The Food and Drug Administration), respectively; these alleles (and additional alleles below) were transduced into virulent strain, 14028, constructing strains 2 and 5, respectively. *damΔ232* (strain 3) was constructed using internal oligonucleotides that serve as PCR primers designed to 20 construct an in-frame 300 bp deletion of defined *dam* sequence. *dcm1::Km* was constructed according to (Julio, S. M., *et al.*, *Molec. Gen. Genet.*, **258**: 178-181 (1998)); the Km resistance determinant is associated with an internal deletion of > 600 bp of *dcm* sequence. The *lrp31::Km* is a null insertion in the *lrp* gene (strain 6). The Dam overproducing strain (strain 4) contains *E. coli* *dam* on a recombinant plasmid (pTP166) 25 in a wild-type background (Marinus, *et al.*, *Gene*, **28**:123-125 (1984)).

For *in vivo* competition studies, bacteria were treated as discussed above, then mutant cells were mixed with wild-type cells at a 1:1 ratio (approximate input bacteria was 500 mutant + 500 wild type). Actual ratios were determined by first plating input bacteria on LB, then scoring one hundred colonies for resistance to appropriate antibiotic(s). Bacteria were injected intraperitoneally into at least five BALB/C mice (with a one-to-one ratio of mutant to wild type as described (Conner, C. P., *et al.*, *Proc. Natl. Acad. Sci. USA*, **14**:4641-4645 (1998)), then after 4-5 days, when mice appeared moribund, they were sacrificed and their spleens isolated, homogenized, diluted and plated. Again, the ratio of mutant to wild-type was determined by scoring one hundred colonies for the mutant phenotype. The competitive index is the ratio of mutant to wild-type bacteria recovered and essentially reflects how fit the mutant strain is compared to the wild-type strain. Thus, those strains that display a competitive index of less than 0.0001 reflect the fact that no mutant strains were recovered from the spleens. Consequently, the mice died as a result of the wild-type strains.

The advantage of the LD<sub>50</sub> assay is that it quantitates large virulence defects. The disadvantage is that it lacks sensitivity and thus subtle but important virulence contributions are often missed. The competitive index is the ratio of mutant to wildtype bacteria recovered from infected tissues after co-inoculation. The competitive index is very sensitive allowing subtle virulence contributions to be detected. However, because of its sensitivity, quantitation of the differences in virulence between two mutants that confer large defects is problematic. Thus the use of the LD<sub>50</sub> and competitive index assays in concert are an effective means to quantitate both large and subtle virulence defects. The competitive index is an additional indicator of how fit the mutant strains are compared to wild type, but does not necessarily directly correlate with full virulence.

The results are shown in Table 1. LD<sub>50</sub> is the dose required to kill 50% of infected animals (LD<sub>50</sub>) assay for each of these strains was compared to that of wild type

(strain 1; (ND, Not determined)). The peroral LD<sub>50</sub> via gastrointubation for all derivatives was determined by infecting at least twelve BALB/c mice; the intraperitoneal (i.p.) LD<sub>50</sub> was determined by infecting at least six mice.

5

TABLE 1

Strain	Genotype	Oral LD <sub>50</sub>	I.P. LD <sub>50</sub>	Competitive Index (I.P.)
1	"wild type"	>10 <sup>+5</sup>	<10	---
2	<i>dam102::Mud-Cm</i>	>10 <sup>+9</sup>	>10 <sup>+4</sup>	<10 <sup>-4</sup>
3	<i>damΔ232</i> (non-polar deletion)	>10 <sup>+9</sup>	>10 <sup>+4</sup>	<10 <sup>-4</sup>
4	wild type, (pTP166) (Dam overproducer)	10 <sup>+8</sup>	>10 <sup>+4</sup>	<10 <sup>-4</sup>
5	<i>mutS121::Tn10</i>	10 <sup>+5</sup>	ND	0.9
6	<i>lrp31::Km</i>	10 <sup>+5</sup>	ND	10.0
7	LT2	ND	2 x 10 <sup>+4</sup>	ND

Since the *dam* insertion could decrease the expression of downstream genes (polar effects), an in-frame, nonpolar *dam* deletion was constructed, and was shown to have the same reduced virulence as the *dam* insertion. Thus, the attenuation was specifically due to the lack of Dam. Furthermore, intraperitoneal inoculation of mice with equal numbers of Dam<sup>+</sup> and Dam<sup>-</sup> *Salmonella* showed that Dam<sup>-</sup> mutants were completely eliminated during growth in the mouse (competitive index assay). Similar results were obtained with strain 4 (Table 1) that overproduces Dam from a recombinant plasmid, suggesting that precise levels of the Dam methylase are required for full virulence. These results show for the first time that the Dam methylase is essential for bacterial pathogenesis.

10 Dam could affect *Salmonella* virulence via an increase in mutation rate caused by abrogation of methyl-directed mismatch repair (MDMR). Since MutS plays an essential

15

role in MDMR, it was determined whether *mutS* Salmonella were attenuated for virulence. The data in Table 1, above, show that in both the oral LD<sub>50</sub> and the competitive index virulence assays, *mutS* *Salmonella* were identical to wild type, indicating that Dam does not affect pathogenesis via the MDMR pathway. Since MutS<sup>-</sup> strains show higher levels of DNA exchange between species than MutS<sup>+</sup> strains, they more readily acquire new virulence determinants (Marinus, *E. coli and Salmonella: Cellular and Molecular Biology, 2nd ed.*, 782-791 (1996)). The fact that MutS<sup>-</sup> strains are fully virulent could explain the high frequency at which *mutS* *E. coli* and *Salmonella* mutants are found amongst clinical isolates (LeClerc, *et al.*, *Science*, 274:1208-1211 (1996)).

Dam and Lrp directly regulate the expression of Pap pili, which are essential for virulence of uropathogenic *E. coli* (O'Hanley *et al.*, *J. Clin. Invest.*, 75:347-360 (1985); and Roberts, *et al.*, *J. Urol.*, 133:1068-1075 (1985)). To determine if Dam affects *Salmonella* virulence through an Lrp-mediated pathway, Lrp<sup>-</sup> *Salmonella* were analyzed (Table 1). *Salmonella* lacking Lrp were fully virulent based on the LD<sub>50</sub> and competitive index assays. These data show that *Salmonella* Lrp is not a virulence factor in mice.

The results discussed above show that adenine methylation is critical for *Salmonella* pathogenesis. DNA methylation of cytosine residues appears to be important for the regulation of biological processes in both plants and animals. Although *Salmonella* contain a DNA cytosine methylase (Dcm), the role of cytosine methylation in this organism is unclear. The *dcm*<sup>-</sup> mutant (*dcm1::Km*) was virulent in the LD<sub>50</sub> and competitive index assays, data not shown. These results demonstrate that methylation of adenine but not cytosine residues is required for *Salmonella* pathogenesis.

DNA adenine methylation has been shown to directly control virulence gene expression in *E. coli* (Braaten, *et al.*, *Cell*, 76:577-588 (1994)). Therefore, it was determined whether Dam regulates *Salmonella* genes that are preferentially expressed in

the mouse, designated as *in vivo* induced (*ivi*) genes. See, Conner, C. P., *et al.*, *Proc. Natl. Acad. Sci. USA*, **14**:4641-4645 (1998); Heithoff, D. M., *et al.*, *Proc. Natl. Acad. Sci. USA*, **94**:934-939 (1997); Mahan, M. J., *et al.*, *Science*, **259**:666-668 (1993); Mahan, M. J., *et al.*, *Proc. Natl. Acad. Sci. USA*, **92**:669-673 (1995); and U.S. Patent No. 5,434,065, 5 all of which are incorporated herein by reference. Dam significantly repressed the expression of over 20 *ivi* genes (2 to 18 fold) when grown in rich medium, eight of which are displayed in Figure 3. Four of the eight fusions are in known genes, all of which have been shown to be involved, or implicated, in virulence: *spvB* resides on the *Salmonella* virulence plasmid and functions to facilitate growth at systemic sites of infection (Gulig, 10 *et al.*, *Mol. Microbiol.*, **7**:825-830 (1993); *pmrB* is involved in resistance to antibacterial peptides termed defensins (Roland, *et al.*, *J. Bacteriol.*, **75**:4154-4164 (1993); *mgtA* and *entF* are involved in the transport of magnesium and iron, respectively (Earhart, *Escherichia coli and Salmonella Cellular and Molecular Biology*, 2nd edition, 1075-1090 15 (1996); and Vescovi, G., *et al.*, *Cell*, **84**:165-174 (1996)). Additional *ivi* genes of unknown function were also Dam-regulated. These results indicate that Dam is a global regulator of *Salmonella* gene expression.

Salmonella pathogenesis is known to be controlled by PhoP, a DNA binding protein that acts as both an inducer and repressor of specific virulence genes (reviewed in Groisman and Heffron *Two-component signal transduction*, 319-332 (1995)). To 20 determine whether the Dam and PhoP regulatory pathways share common genes, the effect of Dam was tested on seven PhoP-activated *ivi* genes, including *spvB*, *pmrB*, and *mgtA*. Figure 4 shows that Dam repressed the expression of these three genes by 2 to 19 fold, and this repression was not dependent on the PhoP protein. Dam did not significantly affect the expression of the remaining four PhoP-activated genes (data not 25 shown). These results indicate that Dam and PhoP constitute an overlapping global regulatory network controlling *Salmonella* virulence.

Binding of regulatory proteins to DNA can form DNA methylation patterns by blocking methylation of specific Dam target sites (GATC sequences (van der Woude, *et al.*, *J. Bacteriol.*, **180**:5913-5920 (1998)). Therefore, further investigation of the interactions between Dam and PhoP were carried out by determining if binding of PhoP (or a PhoP-regulated protein) to specific DNA sites blocks methylation of these sites by Dam, resulting in an alteration in the DNA methylation pattern. Analysis of PhoP<sup>+</sup> and PhoP<sup>-</sup> *Salmonella* showed distinct differences in DNA methylation patterns. Digestion of genomic DNA from PhoP<sup>-</sup> bacteria with *Mbo*I (which cleaves only at nonmethylated GATC sites) resulted in the appearance of DNA fragments that were not present in DNA from PhoP<sup>+</sup> bacteria (Figure 5, see arrows). These results indicate that the PhoP protein (or a PhoP-regulated gene product) blocks Dam methylation at specific GATC-containing sites in the *Salmonella* genome. Alternatively, PhoP<sup>+</sup> and PhoP<sup>-</sup> strains may have different levels of Dam activity which, in turn, may affect DNA methylation patterns. However, this regulation does not occur at the transcriptional level since Dam does not alter PhoP expression, nor does PhoP alter Dam expression (D. M. Heithoff and M. J. Mahan, unpublished material). Further analysis will determine whether these PhoP-protected sites are within regulatory regions of virulence genes, and if DNA methylation directly affects the PhoP regulon by altering DNA-PhoP interactions.

20 **Example 2A: Protective efficacy of Dam<sup>-</sup> *Salmonella* attenuated strains**

Strains which demonstrated attenuation as a result of intraperitoneal or oral challenge of BALB/c mice were further tested for protective immunity against subsequent challenge by the wild-type strain at 10<sup>5</sup> I.P. or 10<sup>9</sup> orally. BALB/c mice were perorally immunized via gavaging with a dose of 10<sup>9</sup> Dam<sup>-</sup> *S. typhimurium*. Five weeks later, the immunized mice were challenged perorally with 10<sup>9</sup> wild-type *S. typhimurium* as described. After five weeks, surviving mice were challenged with the

wild-type 14028 strain as noted in Table 2 below. Survival for four weeks post challenge was deemed full protection. These data demonstrate the potential use of the present invention in developing vaccine strains.

Since Dam<sup>-</sup> mutants were highly attenuated, it was determined whether Dam<sup>-</sup>

5      Salmonella could serve as a live attenuated vaccine. Table 2 shows that all (17/17) mice immunized with a *S. typhimurium* Dam<sup>-</sup> insertion strain survived a wild-type challenge of  $10^{+4}$  above the LD<sub>50</sub>, whereas all nonimmunized mice (12/12) died following challenge.

TABLE 2

Immunization with Dam <sup>-</sup> <i>S. typhimurium</i>	Challenge with $10^{+9}$ wild-type <i>S. typhimurium</i>
None	12/12 dead
<i>dam102::Mud-Cm</i>	17/17 alive
<i>damΔ232</i> (nonpolar deletion)	8/8 alive

10

Virtually no visible effects of typhoid fever were observed subsequent to immunization with Dam<sup>-</sup> *Salmonella*, nor were there visible effects after the wild type challenge. Moreover, because all (8/8) mice immunized with Salmonella containing the 15 nonpolar *dam* deletion (strain ) survived challenge, these data indicate that protection was specifically due to the absence of Dam methylase. The virulence attenuation and effectiveness of Dam<sup>-</sup> mutants as a vaccine (Tables 1 and 2) could be due to the ectopic expression of virulence determinants (Figures 3 and 4) which would likely be deleterious to the growth and/or survival of Salmonella during infection. Thus, ectopic expression 20 provides an explanation as to why the Dam mutant is totally attenuated yet still provides full protection as a live attenuated vaccine.

Colonization studies

The survival of Dam<sup>+</sup> and Dam<sup>-</sup> *Salmonella* in mouse tissues was compared. As shown in Figure 6, Dam<sup>-</sup> bacteria were fully proficient in colonization of a mucosal site (Peyer's patches) but showed severe defects in colonization of deeper tissue sites. Five days after infection, we observed a reduction of three orders of magnitude in numbers of Dam<sup>-</sup> *Salmonella* in the mesenteric lymph nodes (relative to numbers of Dam<sup>+</sup> bacteria) and a reduction of eight orders of magnitude in numbers of Dam<sup>-</sup> *Salmonella* in the liver and spleen. These data show that Dam<sup>-</sup> *Salmonella* survive in Peyer's patches of the mouse small intestine for at least 5 days, providing an opportunity for elicitation of a host immune response. Dam<sup>-</sup> *Salmonella*, however, were unable to cause disease; they either were unable to invade systemic tissues or were able to invade but could not survive.

Example 2B: Protective efficacy of killed Dam derivatives

15        *Determination of whether living Dam<sup>-</sup> or Dam overproducing bacteria are required to elicit a fully protective response.* The ectopic expression of multiple proteins in Dam<sup>-</sup> vaccines (see above and below) suggests the possibility that killed Dam<sup>-</sup> organisms may elicit significantly stronger protective immune responses than killed Dam<sup>+</sup> organisms and thus be used as mucosal vaccine. *In vitro* grown *S. typhimurium* 20 Dam<sup>-</sup> bacteria are killed by exposure to sodium azide (0.02%) and/or UV light, after which the antimicrobial is either washed or dialyzed away from the killed organisms. The efficacy of the whole cell killed vaccine preparation is tested with and without the use of mucosal adjuvants such as cholera toxin, *E. coli* labile toxin, or vitamin D3 (1,25(OH)<sub>2</sub>D<sub>3</sub>). Accordingly, vaccine preparations containing 10<sup>10</sup> killed Dam<sup>-</sup> 25 Salmonella, alone and in combination with mucosal adjuvants, are used to orally immunize BALB/c mice (as described in the Examples). As a dosing regimen, mice are immunized by gavaging once a week for three weeks. Killed wild-type *S.*

*typhimurium* serves as a negative control. The immunized mice are orally challenged with virulent *S. typhimurium* 2 weeks after the last immunization to determine if an effective immune response is generated. If so, mice immunized with the killed vaccine preparation are also challenged with other pathogenic *Salmonella* serotypes (e.g.,

5 *enteritidis*, *choleraesuis*, *dublin*) to determine if the immunity elicited is cross-protective against related strains as is the case for oral administration of Dam<sup>-</sup> *Salmonella* live vaccines. If mice immunized with the dead vaccine preparation are protected two weeks after the final immunization (of three), whether the immunity elicited is long-lasting is determined by challenging immunized mice 7 weeks after the last immunization.

10 Since Dam overproduction may result in the ectopic expression of a new repertoire of potential protective antigens that are not expressed in either the wild-type (Dam<sup>+</sup>) or Dam<sup>-</sup> vaccine strains, the killed vaccine experiments are performed with Dam overproducing strains, alone and in combination with killed Dam<sup>-</sup> organisms. Since the two different vaccine strains may produce two different repertoires of potentially

15 protective antigens, use of them in combination may elicit a superior immune response.

**Example 3: Cross-protection elicited by a Dam<sup>-</sup> *Salmonella***

*Immunization with Dam<sup>-</sup> *Salmonella* elicits a cross-protective response to*

20 *heterologous serotypes.* As shown in Figure 7 and discussed below, Dam<sup>-</sup> mutants ectopically express multiple genes (and presumably proteins) that are normally only expressed during infection. Such ectopic expression of multiple antigens may result in cross-protective immune responses against heterologous serotypes. BALB/c mice were immunized with  $1 \times 10^9$  Dam<sup>-</sup> *S. typhimurium* (serogroup B) administered orally (via

25 gastrointubation) and were challenged eleven weeks later with (100 to 1000 LD<sub>50</sub>) virulent *S. enteritidis* and *S. dublin* (serogroup D). The data in Table 3 show the mice

were protected against a heterologous challenge eleven weeks post immunization. Importantly, the cross-protective immunity was not attributed to the persistence of the vaccine strain in murine tissues, since mice were protected against heterologous challenge greater than six weeks after the vaccine strain was cleared from immunized 5 animals (i.e., after *Dam*<sup>+</sup> organisms could not be detected in Peyer's patches, mesenteric lymph nodes, liver and spleen). The cross-protection elicited is specific to *Salmonella* strains as no protection was elicited against the systemic pathogen *Yersinia pseudotuberculosis* five weeks post-immunization.

10

TABLE 3

Immunization with *Dam*<sup>+</sup> *S. typhimurium* confers cross-protective immunity

Oral immunization with 10 <sup>9</sup> <i>Dam</i> <sup>+</sup> <i>S.</i> <i>typhimurium</i>	Oral challenge with 10 <sup>8</sup> Wild-type <i>S.</i> <i>enteritidis</i>	Oral challenge with 10 <sup>9</sup> wild- type <i>S. dublin</i>	Oral challenge with 10 <sup>8</sup> wild-type <i>S.</i> <i>dublin</i>	Oral challenge with 10 <sup>9</sup> Wild-type <i>S.</i> <i>typhimurium</i>
None	17/17 dead	25/25 dead	11/11 dead	10/10 dead
<i>dam</i> $\Delta$ 232	4/18 alive	4/19 alive	10/19 alive	11/11 alive

Similarly, immunization with *Dam*<sup>+</sup> *S. enteritidis* (dam102::Mud-Cm, following 15 an experimental protocol described above) confers cross-protection against challenge with 10<sup>9</sup> *S. typhimurium* and 10<sup>9</sup> *S. dublin* after five weeks and may confer cross-protection for even longer periods.

*Dam*<sup>+</sup> derivatives ectopically express multiple proteins in vitro. Ectopic expression of multiple proteins in *Dam*<sup>+</sup> strains may contribute to the cross-protection

elicited against heterologous serotypes that share common epitopes. To this end, we have shown that Dam- strains ectopically express of a number of *Salmonella* genes that are normally repressed in vitro.

Two-dimensional protein gel electrophoresis was performed by the method of O'Farrell ((1975) *J. Biol. Chem.* 250: 4007-4021) on whole-cell protein extracts of log-phase *S. typhimurium* grown in Luria broth. Isoelectric focusing using pH 5-7 ampholines (BioRad Laboratories, Hercules, CA) was carried out at 800 V for 17 h. The second dimension consisted of 12.5% polyacrylamide slab gels which were run for 5.5 h at 175 V. Proteins were visualized by silver staining (Merril et al. (1984) *Methods Enzymol.* 104:441-447.). The results are shown in Figure 7. The results show that two-dimensional gel electrophoresis analysis (2-D protein analysis) of Dam-, Dam<sup>+</sup> (wild type) and Dam overproducer (OP) strains grown *in vitro* resulted in the detection of several proteins that were expressed under the Dam<sup>-</sup> condition that were not detected under either the Dam<sup>+</sup> (wild type) or Dam OP (expressing about 100-fold higher Dam than normal) conditions. These data indicate that Dam<sup>-</sup> *Salmonella* ectopically express multiple proteins *in vitro* (and presumably *in vivo*), suggesting that dysregulation of protein expression could provide multiple novel protein targets to be processes and presented to the immune system

2-D protein analysis indicates that Dam overproducing strains of *Salmonella* (*S. typhimurium* ATCC 14028 with plasmid pTP166 that overproduces *E. coli* Dam at about 100-fold the wildtype level) express a number of gene products that are not expressed by Dam<sup>+</sup> (wild type) or Dam<sup>-</sup> *Salmonella* under laboratory growth conditions. We have not detected proteins that are produced by Dam<sup>+</sup> that are not produced by Dam<sup>-</sup> or Dam overproducing strains. Taken together with our observation that Dam overproducing strains are attenuated and elicit protective immunity, these results suggest that Dam overproduction may result in the expression of a different repertoire of antigens than

what is produced in Dam<sup>-</sup> strains. Thus, vaccines consisting of Dam overproducing strains in combination with the Dam<sup>-</sup> strains may be highly cross-protective due to the ectopic expression of two different repertoires of potentially protective antigens.

*Immunity elicited by Dam<sup>-</sup> strains is greater than immunity elicited after a wild-type infection.* One of the most effective virulence properties of a pathogen is the ability to evade host immune responses. Such a "stealth" strategy is achieved by tightly regulating many of its functions to avoid host immune recognition. Thus, as a bacterial protective mechanism, it is likely that many antigens produced by virulent organisms are not produced in sufficient quantities and/or for a sufficient amount of time to elicit a host immune response. However, Dam<sup>-</sup> bacteria may ectopically express multiple antigens that are processed and presented to the immune system, and thus, animals immunized with Dam<sup>-</sup> vaccines may elicit stronger immune responses than animals that survive a natural infection.

The immunity elicited by the Dam<sup>-</sup> vaccine was compared to the immunity elicited after a natural infection with the wild-type strain. BALB/c mice were orally immunized at the LD<sub>50</sub> of the virulent strain *S. typhimurium* (10<sup>+5</sup> organisms) (i.e., one half the mice survived the wild-type immunization) or 10<sup>+5</sup> Dam<sup>-</sup> organisms. Five weeks post-immunization, the immunized mice were challenged with lethal doses of the virulent strain. Table 5 shows that the immunity elicited by the Dam<sup>-</sup> vaccine was at least 100-fold greater (3 of 10 mice survived a 10<sup>+9</sup> challenge) than the immunity elicited in mice that survived an immunization with the wild-type strain (1 of 10 survived a 10<sup>+7</sup> challenge).

Table 5. Mice immunized with Dam<sup>-</sup> vaccines elicit greater protection than mice that survive a wild-type infection.

Oral immunization	Oral challenge with $10^5$ <i>S. typhimurium</i>	Oral challenge with $10^7$ wild-type <i>S. typhimurium</i>	Oral challenge with $10^8$ wild-type <i>S. typhimurium</i>	Oral challenge with $10^9$ <i>S. typhimurium</i>
None	10/10 dead	10/10 dead	10/10 dead	10/10 dead
<i>Dam</i> <sup>+</sup> (at LD <sub>50</sub> )	1/10 alive	10/10 dead	10/10 dead	10/10 dead
<i>dam</i> $\Delta$ 232	5/10 alive	4/10 alive	3/10 alive	

5        Additionally, immunization with Dam<sup>-</sup> organisms showed relatively similar levels of protection over a wide range of challenge doses ( $10^{+7}$  to  $10^{+9}$ ). This suggests that an immunizing dose of  $10^{+5}$  Dam<sup>-</sup> bacteria is below the minimum threshold of organisms required to ensure a productive immune response in all immunized animals. It is possible that the enhanced immunity elicited by Dam<sup>-</sup> strains may be attributed, in part, to the  
10      ectopic expression of Dam repressed-antigens, which may not be produced in sufficient quantities and/or duration during a wild-type infection.

15      *Immunized animals hinder growth of virulent bacteria in systemic tissues.* Dam<sup>-</sup> Salmonella were found to be fully proficient in colonization of Peyer's patches of the mouse small intestine but were severely deficient in colonization of deeper tissue sites (liver and spleen) (Example 1). Dam<sup>-</sup> mutants of *S. typhimurium* are also less cytotoxic to M cells, are deficient in epithelial invasion, and display defects in protein secretion. Pucciarelli et al. (1999) *Proc. Natl. Acad. Sci. USA* 96:11578-11583. Taken together,

these data provide a possible explanation as to why *Dam*<sup>-</sup> mutants are unable to cause disease but are able to elicit a full-protective immune response. Since mice immunized with *Dam*<sup>-</sup> *Salmonella* showed virtually no overt symptoms of disease after challenge with virulent organisms, the fate of wild-type *Salmonella* was compared within 5 immunized vs. non-immunized mice. The data in Fig. 8 show that *Dam*<sup>-</sup> immunized mice carry high loads ( $10^4$ ) of virulent bacteria for at least five days in both mucosal and systemic tissues after wild-type challenge of  $10^9$  organisms. However, the immunized mice have the ability not only to inhibit the growth of these virulent organisms, they are capable of clearing them from both mucosal and systemic tissues (2 out of 4 mice have 10 cleared all virulent organisms from the Peyer's patches, mesenteric lymph nodes, liver and spleen 28 days post challenge). This ability to clear  $10^4$  virulent organisms from the liver and spleen is significant in light of the fact that the i.p. LD<sub>50</sub> is less than 10 organisms. Thus, immunization with *Dam*<sup>-</sup> *Salmonella* hinders the proliferation of wild-type organisms in all tissues tested. The ability to clear a lethal load of virulent 15 bacterium from systemic suggests the possibility that *Dam*<sup>-</sup> vaccines may have therapeutic application to the treatment of a pre-existing microbial infections.

**Example 4: Vaccination of chicken against *S. enteritidis***

A thorough understanding of the dynamics of *S. enteritidis* infection in poultry is 20 essential to the formulation of an effective strategy to interrupt the eggborne transmission of *S. enteritidis* from laying hens to human consumers. *Salmonellae* cause disease by colonizing and invading the intestinal epithelium. In some cases, *Salmonella* penetration through the intestinal mucosa to the bloodstream is followed by widespread dissemination and systemic disease. *S. enteritidis* is an invasive serotype in chicks but 25 has not exhibited a level of pathogenicity for chicks that is markedly different from that of other paratyphoid *Salmonella* serotypes. Popiel and Turnbull (1985) *Infect. Immun.*

47(3):786-792. Chicks can be readily infected, involving both intestinal colonization and invasion to reach internal tissues such as the liver, with *S. enteritidis* from contaminated feed. Hinton et al. (1989) *Vet. Rec.* 124:223.

5 Experimental infections of adult hens with some *S. enteritidis* strains have led to intestinal colonization that persisted for several months, although in studies with other *S. enteritidis* strains the duration of fecal shedding has been considerably shorter. (Gast and Beard, 1990), Gast and Beard (1990) *Avian Dis.* 34:991-993; Shivaprasad et al. (1990) *Avian Dis.* 34:548-557. In one study, intravenously infected birds shed *S. enteritidis* for a longer period than did orally infected birds. Shivaprasad et al. (1990).

10 The effectiveness of various methods of destroying *S. enteritidis* in eggs and egg products has become a topic of increasing importance to public health authorities and the egg industry. Such information is vitally needed in order to provide instructions to consumers and commercial or institutional users of eggs regarding safe preparation of egg-containing foods. Shivaprasad et al. (1990) observed that the time/temperature  
15 requirements for destroying *S. enteritidis* in eggs by various cooking methods did not differ significantly from similar requirements previously determined for *S. typhimurium*. Baker et al. (1983) *Poult. Sci.* 72:1211-1216. Humphrey et al. found that strains of phage type 4 *S. enteritidis*, *S. typhimurium*, and *S. senftenberg*, when inoculated into egg yolk, could survive forms of cooking in which some of the yolk remained liquid. Humphrey et  
20 al. (1989) *epidemiol. Infect.* 103:35-45. Moreover, when eggs were stored at room temperature for 2 days after inoculation, the *S. enteritidis* population grew to such a high level in the yolk that no standard cooking method completely eliminated the *Salmonella*. Storage of *S. enteritidis* cultures at refrigerator temperatures, on the other hand, has been found to increase their sensitivity to heat. Humphrey (1990) *J. Appl. Bacteriol.* 69:493-  
25 497. In another study, *S. enteritidis* phage type 4 in homogenized whole egg was determined to be more heat resistant than phage types 8 or 13a and *S. typhimurium*, but

less than the highly heat-resistant *S. senftenberg* strain 775W. All *Salmonella* strains tested were more heat resistant in yolk than in whole egg or albumin. Humphrey et al. (1990) *Epidemiol. Infect.* 104:237-241.

The vaccines of the present invention, specifically Strain 3, may be effective at 5 eliminating *S. enteritidis* in eggs and egg products. A *dam* *S. typhimurium* vaccine is prepared as described previously. The vaccine is introduced into the chicken by way of oral administration, that is, mixed with the chickens feed and/or water. Once the vaccine has been administered the virulence factors typically repressed by Dam will be expressed and the chicken will elicit an immune response. Since some of these Dam-regulated 10 genes are homologs to those shared by *S. enteritidis*, the *Dam* *S. typhimurium* may elicit cross-protection against *S. enteritidis*, as the data in Example 3 indicate.

**Example 5: Administration of Dam derivative *Salmonella* vaccines to cattle**

15 *Salmonella* is the most commonly isolated infectious enteric bacterial pathogen of dairy cattle and the most common zoonotic disease associated with human consumption of beef and dairy products. In recent years there has been a rise in the incidence and severity of human cases of salmonellosis, in part due to the emergence of the antimicrobial resistant *S. typhimurium* DT104 in cattle populations. Prevalence studies indicate 16 to 73% of U.S. dairy farms are infected with *Salmonella* and up to 50% of 20 cull dairy cows are contaminated with *Salmonella* at slaughter. On-farm *Salmonella* control is important to reduce production losses and human food borne disease.

On large commercial dairy farms it is very common for cattle to be exposed to 25 multiple *Salmonella* serotypes and for calves to become infected shortly after birth. Under these conditions it would be very desirable to have a *Salmonella* vaccine capable of stimulating immunity to heterologous *Salmonella* serotypes.

A. Requirement of Dam for Salmonella infection of cattle, and effectiveness of Dam<sup>+</sup> derivatives as live bovine vaccines

Holstein bull calves 1-3 days of age are used for all of the experiments.

Measurement of total plasma protein is used to assess passive immunity of calves. Only 5 calves with a total plasma protein greater than or equal to 5.5 are used. The Salmonella infection status of the source dairies is determined prior to purchasing the calves by culturing fecal and environmental samples for salmonellae. The Salmonella negative status of calves will be confirmed after purchase by daily fecal Salmonella cultures.

The calves are housed and raised in Animal Biosafety 2 level facilities. Calves are 10 fed 2 quarts of 20:20 milk replaced twice a day and have access to fresh calf grain and fresh water 24 hours a day. Each day at feeding time all calves are given an appetite and attitude score. The appetite score is on a scale of 1 to 4 (1 = consumed 2 quarts of milk, 2 = consumed < 2 but > 1 quart of milk, 3 = consumed < 1 quart of milk, and 4 = consumed no milk). The attitude score is also on a scale of 1 – 4 (1 = standing, 2 = stands with 15 encouragement, 3 = stands with assistance, 4 = unable to stand). Following all of the challenge experiments calves are checked 3 times a day and vital parameters recorded twice a day. Any calf that is unable to stand is considered terminal and is euthanized. No antimicrobial or anti-inflammatory treatments are administered to calves following Salmonella challenge to avoid confounding of the experimental results.

20 *Determination of the safety of live Dam<sup>+</sup> Salmonella vaccines in Holstein bull calves.* The safety of Dam<sup>+</sup> *S. typhimurium* in 1 – 3 day old calves is determined as follows. Eighteen 1 - 3 day old calves are divided into 3 groups of 6. The first group of 6 calves is challenged orally with  $10^9$  Dam<sup>+</sup> Salmonella, the second group with  $10^{10}$  and the third with  $10^{11}$ . For the 3 weeks following challenge each calf in the study is 25 evaluated twice a day to measure pulse and respiratory rate, rectal temperature, appetite, and attitude. Fecal samples are collected from each calf daily for Salmonella culture. At

3 weeks post challenge the calves are euthanized and organs (liver, bile, spleen, mesenteric lymph nodes, ileum mucosa, small intestinal contents, cecum mucosa and cecal contents) cultured for salmonellae.

*Determination of whether Salmonella Dam based vaccines can colonize mucosal and/or systemic tissues.* The kinetics of colonization of bovine tissues is determined for both Dam<sup>+</sup> and Dam<sup>-</sup> *S. typhimurium* after oral administration. The "bacterial load" in the small intestinal contents, ileum mucosa, Peyer's patches, cecum mucosa, cecal contents, mesenteric lymph nodes, liver, and spleen, is determined in calves, as a function of time post infection. Twenty four holstein bull calves are challenged orally with 10<sup>9</sup> Dam<sup>-</sup> *S. typhimurium*. Six calves are randomly assigned to 4 groups to be euthanized at 24 hours and 5, 14, and 28 days post challenge. Tissues are collected from each calf at necropsy for quantitative Salmonella culture. Twenty four holstein bull calves challenged orally with 10<sup>9</sup> Dam<sup>+</sup> *S. typhimurium* are processed identically and serve as a positive control for these experiments.

For Dam<sup>-</sup> Salmonella to be ideal bovine vaccines, they should colonize the Peyer's patches, replicate and persist within the M cells, and present antigens to the underlying immune cells (e.g., macrophages, B cells and T cells) that comprise the Peyer's patch lymphoid follicle. As importantly, they should not colonize deeper tissue such as the liver and spleen, and should eventually be cleared from the Peyer's patches.

If these criteria are met, it is more likely that Salmonella Dam<sup>-</sup> mutants would serve as the basis for a safe, effective bovine vaccine.

*Protective efficacy of Dam<sup>-</sup> *S. typhimurium* vaccination against homologous wild-type challenge.* Twenty calves 1 – 3 days of age are randomly divided into 2 groups of 10 calves. The first group is vaccinated per os with Dam<sup>-</sup> *S. typhimurium* at 1 – 3 days of age. The remaining 10 unvaccinated calves serve as controls. All calves are challenged per os with 10<sup>11</sup> virulent *S. typhimurium* at 5 weeks of age. For the 3 weeks following

challenge each calf is evaluated three times a day and pulse, respiratory rate, rectal temperature, appetite score, and attitude score recorded twice a day. Fecal samples are collected from each calf daily for *Salmonella* culture. All calves that die following challenge are necropsied and organs (liver, bile, spleen, mesenteric lymph nodes, ileum mucosa, small intestinal contents, cecum mucosa and cecal contents) cultured for *salmonellae*. Calves surviving virulent *Salmonella* challenge are euthanized 3 weeks post challenge, necropsied, and organs cultured for *salmonellae* (liver, bile, spleen, mesenteric lymph nodes, ileum mucosa, small intestinal contents, cecum mucosa and cecal contents).

### *Minimum dose regimen required for efficacy in calves and reduced vaccine*

10 *persistence in bovine tissues.* Three important features of any vaccine regimen are i) the dose of the vaccine, ii) the age of the animal, iii) and the persistence of the vaccine in the immunized animal. Minimum dose required to elicit full protection (at 10,000 times the  $LD_{50}$ ) and reduced persistence in murine tissues such as the Peyer's patches, mesenteric lymph nodes, liver, and spleen is determined.

15 B. *Dam*<sup>+</sup> derivatives elicit cross-protection against related (heterologous  
Salmonella serotypes) pathogenic strains

Protective efficacy of Dam<sup>-</sup> *S. typhimurium* vaccination against heterologous wild-type challenge. Three similar virulent *Salmonella* challenge experiments are performed using 3 different challenge organisms. Each experiment involves oral immunization of calves with Dam<sup>-</sup> *S. typhimurium* at 1 – 3 days of age and challenge with virulent *Salmonella* at 5 weeks of age. In the first experiment *S. montevideo* (serogroup C1) is used as the challenge organism, *S. dublin* (serogroup D) in the second, *S. anatum* (Serogroup E1) in the last. Different calves are used for each experiment. For each of these 3 experiments twenty calves 1 – 3 days of age are randomly divided into 2 groups of 10 calves. The first group is vaccinated per os with Dam<sup>-</sup> *S. typhimurium* at 1 – 3 days

of age. The remaining 10 unvaccinated calves serve as controls. All calves are challenged per os with  $10^{11}$  virulent *Salmonella* at 5 weeks of age.

For the 3 weeks following challenge each calf is evaluated three times a day and pulse, respiratory rate, rectal temperature, appetite score, and attitude score recorded

5      twice a day. Fecal samples are collected from each calf daily for *Salmonella* culture. All calves that die following challenge are necropsied and organs (liver, bile, spleen, mesenteric lymph nodes, ileum mucosa, small intestinal contents, cecum mucosa and cecal contents) cultured for *salmonellae*. Calves surviving virulent *Salmonella* challenge are euthanized 3 weeks post challenge, necropsied, and organs (liver, bile, spleen, mesenteric lymph nodes, ileum mucosa, small intestinal contents, cecum mucosa and cecal contents) cultured for *salmonellae*. Comparison of cross-protective immunity elicited in Dam overproducing strains, alone and in combination with Dam<sup>-</sup> mutants, is also performed.

#### C. Killed Dam<sup>-</sup> derivatives of *Salmonella*

15      *In vitro* grown *S. typhimurium* Dam<sup>-</sup> bacteria are killed by exposure to sodium azide (0.02%) and/or UV light, after which the antimicrobial is either washed or dialyzed away from the killed organisms. The efficacy of the whole cell killed vaccine is tested administered per os (oral) and parenterally. For the parenteral vaccine group  $10^6$  killed Dam<sup>-</sup> *Salmonella* is mixed with aluminum hydroxide and quill A adjuvants and

20      administered to calves via intramuscular injection. For the per os vaccination group  $10^{10}$  killed Dam<sup>-</sup> *Salmonella* is administered per os with Vitamin D3 as a mucosal adjuvant. As a dosing regimen, neonatal calves are immunized once a week for three weeks. Killed wild-type *S. typhimurium* administered by the same route and with the same adjuvants serve as a negative control. The immunized calves are challenged with virulent *S.*

25      *typhimurium* 2 weeks after the last immunization using the same protocol as described above to determine if an effective immune response is generated. If so, calves

immunized with the killed vaccine preparation are also be challenged with other pathogenic *Salmonella* serotypes (e.g. *montevideo*, *S. dublin*, and *S. anatum*) to determine if the immunity elicited is cross-protective against related strains. The experiment is repeated using Dam overproducing strains, alone or in combination with killed Dam<sup>-</sup> organisms.

5 Since Dam overproduction may result in the ectopic expression of a new repertoire of potential protective antigens that are not expressed in either the wild-type (Dam<sup>+</sup>) or Dam<sup>-</sup> vaccine strains the killed vaccine experiments are repeated with Dam overproducing strains, alone and in combination with killed Dam<sup>-</sup> organisms.

10

**Example 6: Construction of *dam* mutants in *Vibrio cholerae***

**A. Construction of *V. cholerae* *dam* mutations**

15 *V. cholerae* *dam* mutations are not currently available. Known *V. cholerae* *dam* sequence is used to design primers to PCR amplify the *dam* gene, which is used as a probe to hybridize against an *V. cholerae* lambda clone bank to recover the wild-type *V. cholerae* *dam* clone. The DNA ends of hybridizing clones are sequenced to determine whether they contain the *V. cholerae* *dam* region. Subcloning and further sequencing off the vector ends of these subclones identifies the smallest DNA restriction fragment containing the entire *V. cholerae* *dam* sequence. Non-revertible *dam* deletion mutations 20 associated with an antibiotic resistance marker are constructed according to methods recently developed (Julio, S. M., et al., *Molec. Gen. Genet.*, 258:178-181 (1998)).

The role(s) of *dam* mutants in *V. cholerae* pathogenesis are tested in two different virulence assays for murine cholera (suckling mouse models), the LD<sub>50</sub> and the competitive index, which have been described in Example 1.

25

B. Determination of the protective capacity of *dam* mutants toward the goal of constructing human live attenuated vaccines against *V. cholerae*

As discussed in detail above, *Salmonella* Dam<sup>+</sup> mutants serve as live attenuated vaccines in a mouse model for typhoid fever. The goal of this experiment is to discern 5 whether these desired effects are specific to *Salmonella* DNA adenine methylation or whether Dam<sup>+</sup> mutants also afford protection against *V. cholerae*, and thus may provide a foundation for a new generation of live attenuated vaccines.

Human live attenuated vaccines must be designed to limit the risk of reversion to wild type and to ensure that these strains will not serve as a reservoir for the spread of 10 antibiotic resistance to emerging pathogens. Thus, the next step in this analysis will be to construct an appropriate non-reverting, antibiotic sensitive derivative. Non-polar deletions (no effect on downstream genes in the operon) in *dam* are constructed by removing internal sequences of these genes by standard PCR-based approaches, ligation into a suicide vector, and recovery of the resultant in-frame deletion strains. Deletions of 15 each gene are introduced individually using standard positive-selection suicide vector strategies (Donnenberg, M. S., *et al.*, *Infect. Immun.*, 59:4310-4317 (1991)), resulting in the desired non-reverting, attenuated, antibiotic sensitive vaccine strain. The efficacy of this vaccine is retested as described above. Strains constructed such that Dam is modified (i.e., not completely deleted and/or disabled) are tested, as are Dam 20 overproducing strains.

Example 7: Essentiality of *dam* gene in *Vibrio cholerae* and *Yersinia pseudotuberculosis*

A duplication of *dam* was constructed by integrating a recombinant plasmid 25 containing a Dam mutation into the wild type Dam locus. The resulting duplication contained two copies of *dam*: a mutant copy and a wild type copy. Normally, the

recombinant plasmid segregates at a given frequency, and there is a roughly equal chance that the recombinants (segregants) contain either the mutant or the wildtype gene. If a gene is essential, all segregants of the duplication (which recombines out of the plasmid) is wild type; the recombinants having the mutant gene die. If a recombinant plasmid

5 containing the gene is present, the duplication can segregate either to the mutant or wild type. For *Vibrio cholerae* and *Yersinia pseudotuberculosis*, duplication of the *dam* gene to contain both a wild type and a mutant cannot segregate to the mutant unless a recombinant plasmid providing a wild type *dam* gene is present.

10 The foregoing description is considered as illustrative only of the principles of the invention. Furthermore, since numerous modifications and changes will readily occur to those skilled in the art, it is not desired to limit the invention to the exact construction and processes shown as described above. Accordingly, all suitable modifications and equivalents may be restored to falling within the scope of the invention as defined by the

15 claims which follow.

## CLAIMS

We claim:

1. An immunogenic composition comprising live attenuated pathogenic bacteria  
5 in a pharmaceutically acceptable excipient, said pathogenic bacteria containing a mutation which alters DNA adenine methylase (Dam) activity such that the pathogenic bacteria are attenuated.
2. The immunogenic composition of claim 1, wherein the mutation reduces Dam  
10 activity.
3. The immunogenic composition of claim 2, wherein the mutation eliminates Dam activity.
- 15 4. The immunogenic composition of claim 3, wherein the mutation is a deletion of *dam* gene.
5. The immunogenic composition of claim 1, wherein the mutation causes an increase in expression of Dam.
- 20 6. The immunogenic composition of claim 1, wherein the pathogenic bacteria are *Salmonella*.
7. The immunogenic composition of claim 6, wherein the pathogenic bacteria are  
25 selected from the group consisting of *S. typhimurium*, *S. enteritidis*, *S. typhi*, *S. abortus-ovi*, *S. abortus-equii*, *S. dublin*, *S. gallinarum*, and *S. pullorum*.

8. The immunogenic composition of claim 6, wherein the mutation eliminates Dam activity.

5 9. The immunogenic composition of claim 8, wherein the mutation is a deletion of *dam* gene.

10. The immunogenic composition of claim 6, wherein the mutation causes an increase in expression of Dam.

10 11. The immunogenic composition of claim 7, wherein the pathogenic bacteria are *S. typhimurium*.

15 12. The immunogenic composition of claim 11, wherein the mutation is deletion of *dam* gene.

13. The immunogenic composition of claim 7, wherein the pathogenic bacteria are *S. dublin*.

20 14. The immunogenic composition of claim 13, wherein the mutation is deletion of *dam* gene.

15. The immunogenic composition of claim 7, wherein the pathogenic bacteria are *S. enteritidis*.

25

16. The immunogenic composition of claim 15, wherein the mutation is deletion of *dam* gene.

17. The immunogenic composition of claim 1, wherein the pathogenic bacteria 5 are *Escherichia*.

18. The immunogenic composition of claim 17, wherein the pathogenic bacteria are *E. coli*.

10 19. The immunogenic composition of claim 1, wherein the pathogenic bacteria are *Vibrio*.

20. The immunogenic composition of claim 19, wherein the bacteria are *V. 15 cholerae*.

21. The immunogenic composition of claim 1, wherein the bacteria are *Yersinia*.

22. The immunogenic composition of claim 21, wherein the bacteria are *Y. 20 psuedotuberculosis*.

23. The immunogenic composition of claim 1, wherein the bacteria are selected from the group consisting of *Shigella*, *Haemophilus*, *Bordetella*, *Neisseria*, *Pasteurella* and *Treponema*.

25 24. The immunogenic composition of claim 1, further comprising an adjuvant.

25. The immunogenic composition of claim 1, further comprising a heterologous antigen.

26. The immunogenic composition of claim 1, wherein the pathogenic bacteria  
5 further contain an expression cassette comprising a polynucleotide sequence encoding a heterologous antigen.

27. The immunogenic composition of claim 1, wherein the mutation is non-reverting.

10

28. The immunogenic composition of claim 1, wherein the bacteria contain a second mutation which causes attenuation of the bacteria.

15

30. An immunogenic composition comprising killed pathogenic bacteria in a pharmaceutically acceptable excipient, said pathogenic bacteria containing a mutation which alters DNA adenine methylase (Dam) activity.

20

31. The immunogenic composition of claim 30, wherein the mutation is non-lethal and renders the pathogenic bacteria attenuated.

32. The immunogenic composition of claim 30, wherein the mutation is lethal.

25

33. The immunogenic composition of claim 30, wherein the pathogenic bacteria are *Salmonella*.

34. The immunogenic composition of claim 33, wherein the mutation deletes *dam* gene.

5 35. The immunogenic composition of claim 33, wherein the mutation causes over-expression of Dam.

36. An attenuated strain of a pathogenic bacteria, said bacteria containing a mutation which alters Dam activity such that the bacteria are attenuated.

10

37. The attenuated strain of claim 36, wherein the mutation reduces Dam activity.

38. The attenuated strain of claim 37, wherein the mutation eliminates Dam activity.

15

39. The attenuated strain of claim 38, wherein the mutation is a deletion of *dam* gene.

40. The attenuated strain of claim 36, wherein the mutation causes an increase in 20 expression of Dam.

41. The attenuated strain of claim 36, wherein the bacteria are *Salmonella*.

42. The attenuated strain of claim 39, wherein the bacteria are *Salmonella*.

25

43. The attenuated strain of claim 40, wherein the bacteria are *Salmonella*.

44. A method of eliciting an immune response in an individual comprising administering the immunogenic composition of claim 1 to the individual in an amount sufficient to elicit an immune response.

5

45. A method of eliciting an immune response in an individual comprising administering the immunogenic composition of claim 12 to the individual in an amount sufficient to elicit an immune response.

10

46. A method of eliciting an immune response in an individual comprising administering the immunogenic composition of claim 14 to the individual in an amount sufficient to elicit an immune response.

15

47. A method of eliciting an immune response in an individual comprising administering the immunogenic composition of claim 16 to the individual in an amount sufficient to elicit an immune response.

20

48. The method of claim 45, wherein the immune response persists more than about four weeks after administration.

25

49. The method of claim 46, wherein the immune response persists more than about four weeks after administration.

25

50. The method of claim 47, wherein the immune response persists more than about four weeks after administration.

51. The method of claim 44, wherein the individual is a human.
52. The method of claim 44, wherein the individual is a domestic animal.
- 5 53. The method of claim 52, wherein the animal is a chicken.
54. The method of claim 52, wherein the animal is a cow.
- 10 55. A method of preventing infection by pathogenic bacteria in an individual, comprising administering an immunogenic composition of claim 1 to the individual in an amount sufficient to reduce a symptom associated with infection by the pathogenic bacteria upon infection by the pathogenic bacteria.
- 15 56. A method of treating a pathogenic bacterial infection in an individual, comprising administering an immunogenic composition of claim 1 to the individual in an amount sufficient to reduce a symptom associated with infection by the pathogenic bacteria in the individual.
- 20 57. A method of preventing *Salmonella* infection in an individual, comprising administering an immunogenic composition of claim 6 to the individual in an amount sufficient to reduce a symptom associated with *Salmonella* infection in the individual upon infection by *Salmonella*.
- 25 58. A method of treating *Salmonella* infection in an individual, comprising administering an immunogenic composition of claim 6 to the individual in an amount sufficient to reduce a symptom associated with *Salmonella* infection in the individual.

59. A method of treating an individual infected with a pathogenic bacteria, comprising administering to the individual a composition comprising an agent which alters Dam activity.

5 60. A method of eliciting an immune response against a second species of *Salmonella* in an individual, comprising administering to the individual an immunogenic composition comprising an attenuated first species of *Salmonella*, said first species containing a mutation which alters Dam activity such that the first species of *Salmonella* is attenuated.

10 61. The method of claim 60, wherein the first *Salmonella* species is the first species is *S. typhimurium*.

62. The method of claim 60, wherein the first *Salmonella* species is *S. enteritidis*.

15 63. A method of identifying an agent which may have anti-bacterial activity comprising using an in vitro transcription system to detect an agent which alters the level of transcription from a *dam* gene when the agent is added to the in vitro transcription system, wherein an agent is identified by its ability to alter the level of transcription from 20 the *dam* gene as compared to the level of transcription when no agent is added.

64. The method of claim 63, wherein the *dam* gene is from *Salmonella*.

25 65. A method of identifying an agent which may have anti-bacterial activity comprising using an in vitro translation system to detect an agent which alters the level of translation from an RNA transcript encoding Dam when the agent is added to the in vitro

transcription system, wherein an agent is identified by its ability to alter the level of translation from the RNA transcript encoding Dam as compared to the level of translation when no agent is added.

5 66. The method of claim 65, wherein the Dam is from *Salmonella*.

67. A method of identifying an agent which may have anti-bacterial activity comprising determining whether the agent binds to Dam, wherein an agent is identified by its ability to bind to Dam.

10

68. The method of claim 67, wherein the Dam is from *Salmonella*.

69. A method of identifying an agent which may have anti-bacterial activity comprising the steps of:

15 (a) incubating non-methylated oligonucleotides comprising a Dam binding site with Dam, S-adenosylmethionine, and an agent, wherein said nonmethylated oligonucleotide further comprises a signal;

(b) digesting all nonmethylated target sites, thereby releasing said nonmethylated oligonucleotides; and

20 (c) detecting inhibition of DNA adenine methylase as an increase in said signal due to digestion of said nonmethylated target sites,

wherein an agent is identified by its ability to cause an increase in signal compared to conducting steps (a), (b), and (c) in absence of agent.

25 70. The method of claim 69, wherein said oligonucleotides are tethered to a solid surface.

71. The method of claim 70, wherein said solid surface is a microtiter plate containing avidin and the oligonucleotide comprises biotin. .

72. The method of claim 69, wherein said Dam binding site is a GATC sequence.

5

73. The method of claim 69, wherein the Dam is from *Salmonella*.

74. The method of claim 69, wherein an agent is selected from an inhibitor library consisting of the group selected from polypeptides, organic compounds and

10 inorganic compounds.

75. A method of identifying an agent which may have anti-bacterial activity comprising the steps of:

(a) contacting an agent to be tested with a suitable host cell that has Dam

15 function; and

(b) analyzing at least one characteristic which is associated with alteration of Dam function, wherein an agent is identified by its ability to elicit at least one said characteristic.

20 76. The method of claim 75, wherein the host cell is a bacterium.

77. The method of claim 76, wherein the bacterium is *Salmonella*.

78. A method of preparing the immunogenic composition of claim 1, comprising

25 combining a pharmaceutically excipient with pathogenic bacteria containing a mutation

which alters DNA adenine methylase (Dam) activity such that the pathogenic bacteria are attenuated.

79. A method for preparing attenuated bacteria capable of eliciting an  
5 immunological response by a host susceptible to disease caused by the corresponding or similar pathogenic microorganism comprising constructing at least one mutation in said pathogenic bacteria wherein a first mutation results in altered Dam function.

80. The method of claim 79, wherein a first mutation is introduced into a *Dam*  
10 gene.

81. The method of claim 80, wherein a second mutation is created in a gene that independent of said first mutation, said second mutation causing attenuation of the pathogenic bacteria.

15 82. The method of claim 80, wherein the first mutation alters expression of Dam.

83. The method of claim 82, wherein the first mutation eliminates expression of Dam.

20 84. The method of claim 80, further comprising inserting into said attenuated bacteria an expression cassette comprising one or more structural genes coding for a desired antigen.

85. The method of claim 85, wherein said desired antigen from the group consisting of: Fragment C of tetanus toxin, the B subunit of cholera toxin, the hepatitis B surface antigen, *Vibrio cholerae* LPS, HIV antigens and *Shigella sonnei* LPS.

5




FIGURE 1




FIGURE 2




FIGURE 3





FIGURE 4



**FIGURE 5**




FIGURE 6




FIGURE 7

6/9/01




FIGURE 8A




FIGURE 8B




FIGURE 8C

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/02866

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC 7 A61K39/112 A61K39/02 A61K39/108 A61K39/106 A61K39/102  
 A61K39/10 A61K39/095 C12N1/20 C12N1/21 C12N1/36  
 C12N15/74 A61P31/04 // (C12N1/20, C12R1:42)

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C12R

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>BRAATEN BRUCE A ET AL: "Methylation patterns in pap regulatory DNA control pyelonephritis-associated pili phase variation in <i>E. coli</i>."  <i>CELL</i> 1994,      vol. 76, no. 3, 1994, pages 577-588,      XP000887279      ISSN: 0092-8674      page 577</p> <p>—</p> <p style="text-align: center;">-/-</p>	1-85



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

31 May 2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentdaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
 Fax: (+31-70) 340-3016

Authorized officer

von Ballmoos, P

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/02866

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BRAWER ROLANDO ET AL: "A temperature-sensitive DNA adenine methyltransferase mutant of <i>Salmonella typhimurium</i> ." ARCHIVES OF MICROBIOLOGY JUNE, 1998, vol. 169, no. 6, June 1998 (1998-06), pages 530-533, XP000886607 ISSN: 0302-8933 abstract page 532, right-hand column, paragraph 2 ---	1-43, 78-85
Y	TORREBLANCA JOAQUIN ET AL: "DNA adenine methylase mutants of <i>Salmonella typhimurium</i> and a novel dam-regulated locus." GENETICS 1996, vol. 144, no. 1, 1996, pages 15-26, XP000886604 ISSN: 0016-6731 abstract table 1 ---	44-77
X	TORREBLANCA JOAQUIN ET AL: "DNA adenine methylase mutants of <i>Salmonella typhimurium</i> and a novel dam-regulated locus." GENETICS 1996, vol. 144, no. 1, 1996, pages 15-26, XP000886604 ISSN: 0016-6731 abstract table 1 ---	1-43, 78-85
Y	CARDENAS L ET AL: "ORAL IMMUNIZATION USING LIVE ATTENUATED <i>Salmonella</i> spp. AS CARRIERS OF FOREIGN ANTIGENS" CLINICAL MICROBIOLOGY REVIEWS, US, WASHINGTON, DC, vol. 5, no. 3, 1 July 1992 (1992-07-01), pages 328-342, XP000579484 ISSN: 0893-8512 p. 333, paragraph bridging left and right column ---	44-77
P,X	HEITHOFF DOUGLAS M ET AL: "An essential role for DNA adenine methylation in bacterial virulence." SCIENCE (WASHINGTON D C) MAY 7, 1999, vol. 284, no. 5416, 7 May 1999 (1999-05-07), pages 967-970, XP000887268 ISSN: 0036-8075 the whole document ---	1-85
P,X	GARCIA-DEL PORTILLO FRANCISCO ET AL: "DNA adenine methylase mutants of <i>Salmonella typhimurium</i> show defects in protein secretion, cell invasion, and M cell cytotoxicity." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA SEPT. 28, 1999, vol. 96, no. 20, pages 11578-11583, XP000887265 ISSN: 0027-8424 the whole document ---	1-85

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 00/02866

### Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  

Although claims 44-62 are directed to a method of treatment of the human body, the search has been carried out and based on the alleged effects of the composition.
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.